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ABSTRACT 
Women diagnosed with breast cancer within 5-10 years of pregnancy have 
significantly poorer prognosis than age-matched nulliparous patients. In preclinical 
models, postpartum mammary gland involution is a tumor-promotional window that may 
explain the poor outcomes of postpartum breast cancer in women. During involution, 50-
80% of the milk-producing mammary epithelial cells (MECs) undergo apoptosis. 
Additionally, the MECs themselves become phagocytic and clear the gland of their dying 
neighbors. Peak phagocytosis precedes an influx of M2-activated macrophages with 
immunosuppressive characteristics which are thought to directly contribute to tumor 
promotion in the postpartum gland. The work in this thesis investigates the hypothesis 
that clearance of apoptotic cells during involution induces secretion of immune-
suppressive signals by phagocytic MECs, promoting M2 macrophages and local immune 
suppression. These host events are anticipated to facilitate breast tumor cell immune 
evasion and tumor progression. This hypothesis is based on data that demonstrate 
clearance of apoptotic cells by professional phagocytes promotes M2 macrophages and 
immune suppression through TGF-β and COX-2. To study the role of phagocytic MECs 
in promoting M2 macrophages, an in vitro model was developed in which MECs are 
grown to monolayers with high electrical resistance, modeling the tight cell-cell junctions 
unique to the lactating epithelium. Treatment of these monolayers with TGF-β3 induces 
 
iv 
leakiness of tight junctions, disruption of E-cadherin-based adherens junctions, and 
phagocytosis through novel γ-secretase and β-catenin-dependent mechanisms. To assess 
whether phagocytic MECs contribute to M2 macrophage activation, bone marrow-
derived macrophages were treated with conditioned media from phagocytic or control 
MEC cultures, and macrophage phenotype evaluated by immunoblot and 3D co-culture 
with tumor cells. Phagocytic MEC conditioned media promoted a macrophage phenotype 
consistent with immune suppression, supporting a role for phagocytic MECs in 
promoting a tumor-promotional environment. Additionally, using immunohistochemical 
approaches, COX-2 expression was found to be primarily expressed in normal mammary 
epithelium and elevated during involution, further suggesting a role for MECs in immune 
modulation and tumor promotion in young women postpartum. By further understanding 
the role of phagocytic MECs in regulating the breast microenvironment during 
involution, we hope to identify new targets for postpartum breast cancer therapy. 
 
The form and content of this abstract are approved. I recommend its publication. 







to my matriculating class in the Medical Scientist Training Program; clinical 
preceptors and patients; everyone who’s hit the trail, gym, or diamond with me, or lent 
me reagents, gave scientific advice, or questioned my work; SB; my family; the P.E.O; 
the Program in Reproductive Sciences; the Medical Scientist Training Program; and all 
the administrative staff. My time as a graduate student would not have been the same 
without any of you. 
to my thesis committee and past and present members of the Schedin lab for your 
keen insight, critical analysis, and stimulating discussions regarding my project. 
to my mentor, Pepper Schedin, for inviting me to rotate in her lab in the first 
place, for her scientific enthusiasm, for providing just the right balance of guidance and 
freedom, and for her support. 
and to Jenean O’Brien and Matthew Strutz for simultaneously keeping me going 





TABLE OF CONTENTS 
CHAPTER 
I. MAMMARY GLAND INVOLUTION PROMOTES  
POSTPARTUM BREAST CANCER.....................................................................1 
 
 Dual Effect of Pregnancy on Breast Cancer Risk....................................................1 
 Poor Prognosis of Postpartum Breast Cancer..........................................................3 
 Postpartum Mammary Gland Involution is Tumor-Promotional.............................5 
 
Postpartum Mammary Gland Involution.....................................................5 
 
  Tumor-Promotional Attributes of Postpartum Involution...........................9 
 
  Targeting Involution for Postpartum Breast Cancer Prevention................12 
  
II. APOPTOTIC CELL CLEARANCE BY MAMMARY EPITHELIAL 
CELLS AND POSTPARTUM TUMOR PROMOTION......................................14 
 
A Phagocytic Role for Mammary Epithelial Cells in the Postpartum 
Mammary Gland....................................................................................................14 
 
Apoptotic Cell Recognition and Clearance............................................................15 
 
Apoptotic Cell Clearance Promotes an Immunosuppressive 
Microenvironment..................................................................................................18 
 
Phagocytic Mammary Epithelial Cells as Orchestrators of a 
Tumor-Promotional Immune Environment...........................................................20 
 
Hypothesis and Aims.............................................................................................23 
 
III. A NOVEL IN VITRO MODEL OF PHAGOCYTIC  




Material and Methods............................................................................................31 
  
 Human Tissue Acquisition.........................................................................31 
 




 Immunohistochemical (IHC) and TUNEL Staining, Image 
  Acquisition, and Quantification of Breast and Mammary Tissues............32 
 
  In Vitro Phagocytosis Assay......................................................................33 
 
  Immunocytochemistry of Mammary Epithelial Cells in Culture..............35 
 
  γ-secretase Activity Assay.........................................................................35 
 
  Immunoblotting and Quantification...........................................................36 
 
  RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR....................37 
 




 Discussion..............................................................................................................54  
 
IV. COX-2 EXPRESSION BY MAMMARY EPITHELIAL CELLS AS A 
 POTENTIAL CHEMOPREVENTIVE TARGET FOR YOUNG 




 Material and Methods............................................................................................62 
 
  Human Tissue Acquisition.........................................................................62 
 
  Animal Husbandry, Reproductive Staging, and 
Hormone Stimulation.................................................................................63 
 







   
  Wide Range in COX-2 Expression across Premenopausal Human 
  Breast Tissue..............................................................................................67 
 
  Evidence for Ovarian Hormone Regulation of COX-2.............................72 
 
   
 
viii 
Coordinated COX-2 Expression in Normal Epithelium, DCIS, 
  and Breast Cancer......................................................................................74 
 






 Summary of Key Findings.....................................................................................85 
 








A.  EFFECTS OF PHAGOCYTIC MAMMARY EPITHELIAL CELLS 




 Materials and Methods.........................................................................................125 
 
  Generation of Apoptotic Cells.................................................................125 
 
  Phagocytosis Assay and Harvesting of Conditioned Media, 
  RNA, and Protein.....................................................................................125 
 
  Bone Marrow-Derived Macrophage (BMDM) Maturation 
  and Activation..........................................................................................126 
 
  Generation of L-Cell Conditioned Media................................................127 
 
  Immunoblotting........................................................................................128 
 
  Cytokine Array.........................................................................................128 
 
  Prostaglandin E2 (PGE2) ELISA..............................................................129 
   
  RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR..................129 
 
  3D Tumor Cell-Macrophage Co-Culture, Organoid Quantification, 






  VEGF, Cytokine, and PGE2 Secretion by Efferocytic Mammary 
Epithelial Cells.........................................................................................132  
 





LIST OF TABLES 
TABLE 
3-1. Specific pre-treatment and antibody information for IHC staining 
of human and rat tissue..........................................................................................33 
 
3-2. Primary and secondary antibody information for  
immunocytochemistry of mammary epithelial cells in culture..............................35 
 
3-3. Transcription factors associated with EMT and mesenchymal 
markers are not upregulated following TGF-β3 treatment of  
EpH4 cell monolayers............................................................................................46 
 
4-1. Clinical characteristics of cases analyzed by reproductive stage...........................69 
 
4-2. Clinical characteristics of cases used for normal adjacent, DCIS, 
IDC and serial biopsy analyses..............................................................................77 
 










1-1.  A transient increase in breast cancer risk postpartum..............................................2 
 
1-2. Postpartum mammary gland involution...................................................................6 
 
2-1. Apoptotic cell “eat me” signals and phagocytic receptors.....................................17 
 
2-2. Model of pro-tumorigenic immune modulation by phagocytic 
mammary epithelial cells.......................................................................................24 
 
3-1. Schematic of tight and adherens junctions.............................................................29 
 
3-2. Mammary epithelial cells are phagocytic during postpartum 
involution across species........................................................................................40 
 
3-3. TGF-β3 promotes phagocytosis in EpH4 cell monolayers....................................43 
 
3-4. TGF-β2 expression in the mammary gland is high during 
lactation and decreases through involution............................................................45 
 
3-5. Phagocytosis following TGF-β3 treatment is associated with 
decreased junctional integrity................................................................................46 
 
3-6. Reorganization of adherens junctions and increased γ-secretase 
activity during involution in the rat mammary gland............................................50 
 
3-7. Notch cleavage is not observed in EpH4 cell monolayers 
following TGF-β3 treatment..................................................................................52 
 
3-8. TGF-β3 induces phagocytosis in EpH4 cell monolayers 
through γ-secretase and β-catenin..........................................................................53 
 
3-9. Proposed model of phagocytosis induction in mammary 
epithelial cells following TGF-β3 treatment.........................................................54 
 
4-1. Confirmation of human and rodent COX-2 antibody specificity..........................65  
 
4-2. Quantification of COX-2 staining intensity using 
Aperio Analysis Software. ....................................................................................68 
 
4-3. COX-2 expression in histologically normal epithelium does not 




4-4. Normal breast tissue COX-2 expression is primarily epithelial and 
regulated by pregnancy and postpartum involution..............................................70 
 
4-5. COX-2 IHC expression in normal adjacent breast epithelium is 
independent of age and BMI.................................................................................72 
 
4-6. COX-2 is upregulated in the rat mammary gland during pregnancy and 
postpartum involution............................................................................................73 
 
4-7. Evidence for ovarian hormone regulation of COX-2 in rat mammary 
epithelium..............................................................................................................75 
 
4-8. COX-2 expression in normal breast epithelium associates with COX-2 
expression in matched DCIS and IDC...................................................................78 
 
4-9. COX-2 expression in normal, DCIS, and IDC in postpartum, 
 pre-menopausal women.........................................................................................79 
 
4-10. Model of the relationships between COX-2 expression in the normal 
epithelium, DCIS, and invasive breast cancer in premenopausal women.............82 
 
A-1. Characterization of EpH4 cells after culture in 
apoptosis-inducing conditions.............................................................................132 
 
A-2. Schematic of experimental conditions for in vitro efferocytosis assay...............134 
 
A-3. Cytokine production by mammary epithelial cells that have engulfed 
apoptotic cells......................................................................................................135 
 
A-4.  COX-2 expression and PGE2 production by efferocytic mammary 
epithelial cells......................................................................................................138 
 
A-5. Conditioned media from efferocytic mammary epithelial cells 
promotes macrophages with both classically and alternatively  
activated characteristics.......................................................................................140 
 
A-6. Macrophages activated with conditioned media from TGF-β3-treated 








Dual Effect of Pregnancy on Breast Cancer Risk 
The effect of pregnancy on a woman‘s risk of developing breast cancer is 
dynamic. Following pregnancy, women experience a transient increase in breast cancer 
risk that peaks approximately five to six years postpartum and may persist for up to thirty 
years
1-5
. Over time, the transient increase in breast cancer risk following pregnancy 
diminishes, such that a crossover in risk occurs and women who have given birth have a 
lower breast cancer risk than age-matched women who have never given birth
1, 3, 6, 7
 
(Figure 1-1). This phenomenon of a transient increase in breast cancer risk postpartum 
followed by protection was first described by Janerich and Hoff in the early 1980s and is 
referred to as the ―dual effect‖ of pregnancy
8
. It should be noted that while women 
experience a transient increase in breast cancer risk following pregnancy, most breast 
cancers arise in older women and, therefore, the lifetime cumulative effect of pregnancy 
is protective against breast
3
. However, though breast cancer is diagnosed more frequently 
in older women, a significant number of young women are still affected by a breast 
cancer diagnosis. In the United States in 2010, ~13% of all breast cancers were diagnosed 
in women under the age of 45, accounting for nearly 18,600 cases of invasive breast 
cancer and 6,500 cases of ductal carcinoma in situ (DCIS)
9
. Further, the proportion of 
advanced breast cancers diagnosed in young American women is increasing at a rate of 
2% per year, making young women‘s breast cancer an emerging concern
10
. Because 
many of these young women may have a recent pregnancy associated with their breast 
2 
cancer diagnosis, it is necessary to understand the factors that drive increased breast 
cancer risk during the postpartum period. 
 
 
Figure 1-1. A transient increase in breast cancer risk postpartum. All women 
experience a transient increase in breast cancer risk following pregnancy compared to 
age-matched women who have never given birth (dotted line). This increased risk is 
lowest for women who have their first child at less than 25 years of age, and increases 
with increasing age (P1=age at first birth). Women who are less than 25 years of age 
when they have their first child are at increased risk for breast cancer for approximately 
10 years postpartum before crossing over into pregnancy-induced protection. In women 
who are older than 30, the crossover into protection (arrows) does not occur for nearly 30 
years postpartum. Data compiled from G. Albrektsen, University of Bergen, Norway; 
figure adapted from Schedin P, Nature Reviews Cancer, 2006.  
 
To date, the age of a woman when she has her first child has been identified as the 
primary variable affecting the magnitude of increased breast cancer risk following 
pregnancy, such that increased breast cancer risk is associated with increasing maternal 
age. In data collected from a Norwegian cohort of 23,890 women, breast cancer risk 
increased with increasing maternal age, with the greatest increase in risk associated with 
first birth after the age of 30
4
. Furthermore, in a cohort of 74,787 women from Sweden, 
3 
increased risk was most pronounced in women who were older than 35 at the time of 
their first child
1
. While there is relative consensus that age of first birth is a primary 
factor behind the magnitude of increased breast cancer risk following pregnancy, there 
are conflicting data regarding the effect of subsequent pregnancies on this risk. Work 
from Albrektsen et al. support each pregnancy being associated with its own independent 
transient increase in breast cancer risk
4
. Rosner at al. identify age at first birth as having a 
dominant effect on pre-menopausal breast cancer risk
11
. In this study, an increase in pre-
menopausal breast cancer risk of 1.7% was identified for each year increase in maternal 
age at time of first birth, with an increase in risk of only 0.4% associated with increasing 
maternal age of subsequent pregnancies
11
. Finally, work from Liu et al. described a lower 
increase in breast cancer risk following pregnancy in diparous women compared to 
uniparous women, suggesting that subsequent pregnancies may actually lower risk
2
. 
Cumulatively, these studies demonstrate that older age at first birth increases breast 
cancer risk following pregnancy, whereas the risk associated with subsequent 
pregnancies requires further investigation. 
Poor Prognosis of Postpartum Breast Cancer 
In addition to pregnancy being associated with increased breast cancer risk 
postpartum, pregnancy-associated breast cancers (PABC) also have a poorer prognosis. 
Women diagnosed with breast cancer during or within 1 year of a recent pregnancy are 
reported to have increased rates of recurrence and decreases overall survival compared to 
non-pregnant age- and stage-matched controls
12-14
. PABC cases can be separated into two 
subsets: women diagnosed during pregnancy, and those diagnosed in the period of time 
following pregnancy
15
. Distinguishing between these subsets is important and necessary 
4 
when considering the etiology of poor outcomes associated with PABC. Breast cancer 
patients who are diagnosed during pregnancy present with more advanced disease than 
non-PABC patients, but when age and stage at time of diagnosis are controlled for, 
pregnancy itself is not associated with poorer outcomes
16-20
. However, when one looks 
only at cases diagnosed in the postpartum period, a recent pregnancy itself is 
independently associated with poorer outcomes. Stensheim et al. report 11 year survival 
rates of 33% for breast cancer cases diagnosed within 7 months postpartum, compared to 
69% for non-PABC cases, while survival rates for cases diagnosed during pregnancy 
were not significantly different than non-PABC associated cases
21
. These data are further 
supported by subsequent work from Johansson et al. reporting similar results for ten year 
survival rates
22
. Altogether, these data suggest that poor prognosis of PABC is 
predominately drive by postpartum breast cancer cases and not by breast cancers 
diagnosed during pregnancy. 
Decreased survival rates for postpartum breast cancer are, in part, a function of 
how recently a woman is diagnosed with breast cancer following her pregnancy. Looking 
at 15 year survival rates and women diagnosed within 12, 13 to 48, or greater than 48 
months postpartum, survival rates were lowest in women diagnosed within 12 months of 
given birth (38%) compared to diagnosis between 13 and 48 months or greater than 48 
months (51 and 60%, respectively)
23
. Importantly, all women diagnosed within 48 
months of giving birth had a significantly lower survival rate than nulliparous women
23
. 
Additionally, in recent work by Callihan et al., breast cancer diagnosis within 5 years of a 
recent pregnancy was independently associated with a 2.8 times higher risk for metastasis 
and a 2.7 times higher risk for mortality compared to nulliparous cases
24
. This study is 
5 
unique in the large number of cases with known clinical data (n=619) and indicates that 
postpartum breast cancer carries a significantly worse prognosis when diagnosed within 5 
years postpartum, an assertion also supported by earlier, less rigorous studies
25-27
.  
Both exposure to pregnancy hormones and delayed diagnosis have been 
postulated to contribute to the poor prognosis of postpartum breast cancer; however, this 
is not consistent with the outcomes data described above indicating a poorer prognosis 
specifically associated with postpartum cases and not those diagnosed during pregnancy. 
As described by others, if the increased mortality rate associated with postpartum breast 
cancer was driven by either delayed diagnosis or pregnancy hormones, one would expect 
cases diagnosed during pregnancy to have similarly poor survival rates as cases 
diagnosed postpartum
3, 15
. Additionally, one would predict based on these hypotheses that 
the decreased survival associated with postpartum diagnosis could be attributed to more 
advanced cancer or subtype. Yet, even after controlling for stage and subtype, breast 
cancer patients diagnosed postpartum still have a poorer prognosis and increased 
metastasis than age-matched nulliparous patients
24
. Based on these data, it has been 
proposed that an event beyond the pregnancy itself is likely the primary factor underlying 
the poor prognosis of postpartum breast cancer
3
. Postpartum mammary gland involution 
has been identified as one such event that may contribute to increased metastasis and 
poor outcomes of postpartum breast cancer
3, 28
.  
Postpartum Mammary Gland Involution is Tumor-Promotional 
Postpartum Mammary Gland Involution 
The mammary gland is a dynamic organ, undergoing most of its development 




the nulliparous state, the structure of the rodent mammary gland consists of a basic 
network of ductal epithelium with few alveoli embedded within a stroma consisting of 
adipocytes, extracellular matrix, fibroblasts, immune cells, blood vessels, and lymphatics. 
With each round of ovarian hormone cycling, the mammary alveoli undergo a small 
round of proliferation and regression in response to the rise and fall of ovarian hormones. 
Upon pregnancy, the mammary epithelium proliferates extensively to prepare for 
lactation, and it is not until lactation that that gland is considered, by most, to reach its 
fully differentiated state. Following lactation, or pregnancy if nursing does not occur, the 
mammary gland undergoes an extensive tissue remodeling process to return back to a 
non-secretory structure that morphologically resembles the simple ductal network of the 
pre-pregnant gland. The process of the mammary gland returning to a non-secretory state 
is known as postpartum involution (Figure 1-2). 
 
 
Figure 1-2. Postpartum mammary gland involution. Following lactation, or pregnancy 
if lactation does not occur, the mammary gland undergoes postpartum involution to 
return to a non-secretory state, which is morphologically similar to the virgin mammary 
gland. A) Whole mounts of rat mammary glands, adapted from Schedin P et al., J 




Postpartum involution has been characterized as occurring in two phases—a 
reversible cell-death phase with maintenance of lobuloalveolar structures, followed by a 
non-reversible, tissue-remodeling phase with additional cell death and lobuloalveolar 
collapse
30
. Through teat-sealing experiments, it was shown that the initial phase of 
involution is regulated locally by milk stasis and lasts approximately 48 hours after the 
cessation of lactation
31, 32
. A multitude of factors are required for apoptosis initiation to 
occur unabatedly (see
33, 34
), with the main pathways involved include activation of Stat3, 
TGF-β, NF-kB, and death receptor signaling
33, 35-38
. Cell death during involution is 
characterized as occurring through an initial phase of lysosomal-mediated cell death, 
independent of executioner caspases, followed by caspase-dependent apoptosis
39
. 
Additionally, macrophages are demonstrated to be essential for cell death during 
involution, although their specific role is yet to be determined
40
. 
While it is well regarded that the initial phase of mammary gland involution is 
induced by milk stasis, it is unknown what the inciting factor is that triggers the initiation 
of cell death. One hypothesis is that cell mechanical stretch due to buildup of milk within 
the alveolar lumens turns on cell death programs. In support of this theory, non-
transformed murine mammary HC11 cells exposed to mechanical strain have increased 
Lif expression, ERK1/2 phosphorylation, and Stat3 activation, along with decreased Akt 
activation, all characteristics of early involution
41
. It should be noted however, that 
neither stretch nor Stat3 activation is sufficient to initiate cell death during involution, as 
apoptosis does not occur in the absence of macrophages, even though distension of 
alveolar lumens and Stat3 activation are observed
40
. Alternatively, buildup of an inciting 
factor within the milk or epithelial cells themselves as a result of lactation cessation is 
8 
also proposed as a means to initiate cell death during involution. In a 3D cell culture 
model of mammary acini, reactive oxygen species were shown to induce apoptosis only 
within the luminal cell layer, similar to cell death during involution
42
. This observation 
lead authors to speculate that reactive oxygen species resulting from milk breakdown 
may be a potential mechanism for ―selective involution‖ of the secretory epithelium
42
. 
Additionally, increased calcium build-up within the secretory cells themselves has also 
been postulated as an initiator of cell death during involution as downregulation of the 
calcium transporter PMCA2 is observed within 24 hours of lactation cessation, leading to 
calcium accumulation within the epithelial cells
43, 44
. Furthermore, decreased PMCA2 
expression within the mammary epithelium leads to activation in Stat3 and NK-kB, 
similar to the initial phase of involution
44
. Given the importance of successful involution 
for the ability to nurse future offspring, it is likely that there are redundant mechanisms 
involved in early cell death initiation. 
Following the first wave of apoptosis, involution progresses to a protease-
dependent, non-reversible tissue remodeling phase characterized histologically by 
collapse of lobuloalveolar structures and adipocyte repopulation
30
. During this second 
phase of involution there is downregulation of protease inhibitors and an upregulation of 
proteases, including matrix metalloproteinases (MMPs) 2, 3, 9, and 11, interleukin-1β 
converting enzyme (ICE), and urokinase-type plasminogen activator (uPA)
45-49
. 
Downregulation of MMPs and uPA by systemic glucorcorticoid administration up to 
three days post-wean delays this phase of involution without disrupting the initial wave 
of cell death, indicating that this tissue remodeling phase does not begin until 48-72 hours 
post-wean
30, 50
. Furthermore, these data, coupled with preservation of lobuloalveolar 
9 
structures with maintenance of systemic hormones in the presence of alveolar cell death, 
indicate the tissue remodeling phase of involution is dependent on changes in systemic 
hormones
31
. Roles for proteases during involution include basement membrane 
breakdown, extracellular matrix remodeling, and regulation of adipocyte differentiation 
(reviewed by Green and Lund
51
), as well as possibly immune cell recruitment and 
function
52, 53
. While the entire process of mammary gland involution has been studied as 
a model for programmed cell death for over two decades, most of the signaling pathways 
studied address the execution of cell death and tissue remodeling, rather than the 
initiation of cell death during involution, which remains unknown. 
Tumor-Promotional Attributes of Postpartum Involution 
 The tissue remodeling aspect of postpartum involution has been characterized as 
sharing multiple attributes with wound healing, a process known to be tumor 
promotional
47, 54-59
. These attributes include increased protease activity (as described 
above), release of bioactive extracellular matrix fragments, accumulation of collagen, and 
immune cell infiltrate
54-60
. Based on the similarities between wound healing and 
postpartum involution, the involution-hypothesis has been proposed to account for the 
increased metastasis and poor prognosis of postpartum breast cancer
28
. This hypothesis 
predicts that the wound healing attributes of postpartum involution contribute to a 
microenvironment that promotes growth and metastasis of pre-existing tumor cells 
present in the mammary gland
28
.  
In support of the involution-hypothesis, a tumor-promotional role for the 
extracellular matrix (ECM) of the involuting mammary gland has been identified. When 
MDA-MB-231 human tumor cells or D2.OR murine mammary tumor cells are grown on 
10 
ECM isolated from involuting rat mammary glands, more invasive structures are formed 
when compared to cells cultured on matrix isolated from nulliparous rat mammary 
glands
47, 61
. Additionally, when mammary ECM from involuting rats is injected along 
with tumor cells in an orthotopic xenograft models, primary tumor growth and metastasis 
are promoted when compared to mammary ECM isolated from nulliparous animals
47, 61
. 
These data indicate that mammary ECM alone is sufficient to enhance tumor growth and 
metastasis. Possible mediators of increased metastasis in this model include increased 




Collagen deposition and remodeling have also been identified as a having a role 
in tumor promotion during involution. Increased collagen deposition is observed in both 
human and rodent mammary glands during postpartum involution, peaking during mid- 
to late-involution
55, 62
. Not only is collagen more abundant during involution, the 
structure of the collagen changes such that collagen fibers are more radially aligned, or 
perpendicular to the epithelium during this time
62
. Importantly, radially aligned collagen 
fibers are associated with poorer outcomes in breast cancer patients
63
, consistent with the 
organization of involuting collagen contributing to a poor prognosis in postpartum breast 
cancer patients. One possible mechanism by which collagen promotes postpartum breast 
cancer is through upregulation of cyclooxygenase-2 (COX-2) expression in tumor cells
62
. 
In a mouse model of postpartum breast cancer, human breast DCIS cells injected into 
involuting mammary glands upregulate COX-2 when in close proximity to collagen 
fibers, and form larger, more invasive tumors than cells injected into nulliparous animals. 
When dissociated from primary tumors, involution group tumor cells are more invasive 
11 
in 3D cell culture than nulliparous group tumor cells, in a collagen I and COX-2 
dependent manner. In this animal model, COX-2 inhibition during involution decreases 
tumor growth and local invasion, as well as collagen levels, suggesting a feed-forward 
loop between COX-2 and collagen in postpartum tumors
62
. Furthermore, in 3D cell 
culture studies, tenascin-C was also identified as a potential ECM mediator of an invasive 
tumor cell phenotype during involution downstream of COX-2
61
. 
Tissue remodeling during involution is also associated with an influx of immune 
cell populations. Similar to the initial stages of wound healing, there is an upregulation of 
the neutrophil chemoattractant Cxcl1 (Gro-1) in the involuting mammary gland that is 
associated with an influx of neutrophils
59
. In addition, dendritic cells have also been 
identified as entering the gland during early involution (Martinson and Schedin, 
unpublished). This is followed by increased monocyte chemotactic protein-1 (MCP-
1/CCL2) and recruitment of macrophages into the gland
55
, as well as a dramatic increase 
in regulatory T cells (Martinson and Schedin, unpublished). While each of the immune 
cell types in the involuting gland have the ability to be tumor promotional, the remainder 
of this section will focus on the role of macrophages. Involution macrophages have been 
characterized as belonging to a macrophage subset known as alternatively activated 
macrophages
55
, which has important implications in tumor promotion. During 
maturation, monocytes mature into a spectrum of macrophage phenotypes in response to 
the surrounding cytokine milieu, and obtain properties ranging from antigen-presentation 
and immunosurveillance to tissue remodeling and immunosuppression. These two ends 
of the spectrum have been defined by some as classically activated/M1 macrophages and 
alternatively activated/M2 macrophages, respectively
64-66
. Classically activated 
12 
macrophages are activated by TNFα, IFNγ, IL-1β and LPS, and can be identified by 
inducible nitric oxide synthase (iNOS), IL-1, and IL-12 expression. These macrophages 
are considered tumor suppressive due to their pro-inflammatory properties and role in 
immunosurveillance. In contrast, IL-4, IL-10 and IL-13 promote alternatively activated 
macrophages, which can be identified by expression of arginase-1 (arg-1), mannose 
receptor (MR), FIZZ1, Ym1, and IL-1RA
64-66
. Alternatively activated macrophages 
function in immunosuppression, wound repair and tissue remodeling
64, 67
. Importantly, 
macrophages can exist anywhere along the spectrum of classical and alternative 
activation, and may have both classical and alternative characteristics. Similarly, 
macrophage maturation is plastic, and even after a macrophage is activated it may 
respond to additional environmental cues to further change, or even switch phenotype
68
. 
Tumor-promoting macrophages or tumor-associated macrophage belong to the 
alternatively activated macrophage subset. Because macrophages recruited into the 
involuting mammary gland are of the alternatively activated phenotype
55
, they may 
contribute to the promotion of tumor cells within the gland during this time. The role of 
TAMs in breast cancer promotion is further explained in Chapter II. 
Targeting Involution for Postpartum Breast Cancer Prevention 
 Postpartum involution had been identified as a developmental window that may 
be targeted for postpartum breast cancer chemoprevention by reducing progression
69
. 
Cancer chemoprevention can occur at three levels—primary, secondary, and tertiary 
prevention. Primary prevention is designed to prevent the occurrence of cancer, while 
secondary and tertiary prevention are directed toward preventing progression of cancer 
and recurrence, respectively. In breast cancer patients, subsets of indolent breast cancer 
13 
lesions have been identified which contain a disrupted basement membrane and early 
stage tumor cells in direct contact with the mammary stroma
70, 71
. Based on the 
involution-hypothesis, it is predicted that these tumor cells are then promoted when in 
contact with the involution microenvironment
3
. An extension of this hypothesis is that the 
involution process may be targeted to prevent progression of these lesions. The concept 
that involution can be targeted for postpartum breast cancer prevention is supported by 
studies demonstrating that, in rodent models of postpartum breast cancer, tumor 
promotion can be ameliorated by treatment with specific and non-specific COX-2 
inhibitors during the involution window (discussed more in Chapter IV)
61, 62
. By further 
understanding the process of postpartum involution, we hope to identify additional 
factors that contribute to mammary tumor promotion, and as such represent unexplored 
avenues for prevention and targeted treatment of postpartum breast cancer.  
14 
CHAPTER II 
APOPTOTIC CELL CLEARANCE BY MAMMARY EPITHELIAL CELLS AND 
POSTPARTUM TUMOR PROMOTION 
A Phagocytic Role for Mammary Epithelial Cells in the Postpartum Mammary 
Gland 
 During postpartum involution, an estimated 50-80% of the milk-producing, 
alveolar mammary epithelia undergo apoptosis to return the gland to a non-secretory 
state
72
. Rapid and efficient clearance of these apoptotic cells is essential, since persistence 
of apoptotic cells can result in release of cell fragments into the local environment and 
subsequent autoimmunity
73
. The process of phagocytosis of apoptotic cells is referred to 
as efferocytosis, taken from the Latin word ―effero‖, meaning to take to the grave
74
. 
Overall, efferocytosis is primarily the function of ―professional‖ phagocytes such as 
monocytes, macrophages, and polymorphonuclear granulocytes
75
. While macrophages 
and neutrophils are recruited into the involuting mammary gland, they are thought to 
have a limited role in apoptotic cell clearance, as discussed further below. Rather, the 
mammary epithelial cells themselves function as the primary cell type responsible for 
clearance of their apoptotic neighbors during postpartum involution
76
. 
 Evidence of apoptotic cell clearance by the nearby epithelium during involution 
was first reported by Walker at al. in 1989, and since that time the viable, neighboring 
epithelial cells have been identified at the primary efferocytes during involution. The first 
data unveiling mammary epithelial cells at the dominant phagocytes responsible for 
apoptotic cell clearance during involution came from morphometric analyses of C57BL/6 
mouse mammary glands across involution time points
76
. Apoptotic cells, as determined 
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by cleaved caspase-3 staining, were highest in the mammary gland through the first 2.5 
days of involution, then subsequently decreased through involution day 4 to reach 
baseline levels. Cleaved caspase-3 positive cells were observed to be shed apically into 
the alveolar lumens and then found within the phagolysosomes of the viable epithelium, 
with peak engulfment of apoptotic cells by mammary epithelial cells at involution day 3. 
Importantly, while macrophages were also observed in the involuting glands, their 
numbers remained relatively low and constant until increasing at involution day 4, 
suggesting efferocytosis is not a primary function of the macrophages recruited into the 
gland during involution. This notion is further supported by subsequent quantitative 
analyses of macrophage influx into the involuting mammary gland. These analyses 
demonstrate peak numbers during mid- to late-involution
55
, which is after the majority of 
apoptotic cell clearance has occurred. 
Apoptotic Cell Recognition and Clearance 
 The process of apoptotic cell engulfment has been characterized as occurring in 
four distinct steps: recruitment of phagocytes to the apoptotic cells, recognition of the 
apoptotic cell by the phagocyte, engulfment of the apoptotic cells, and digestion of the 
apoptotic cell by the phagocyte
77
. During mammary gland involution, the primary 
phagocyte responsible for apoptotic cell clearance—the mammary epithelial cell—is 
already in close proximity to the apoptotic targets, bypassing the first step of the 
clearance process. The second step of the process, recognition of the apoptotic cell by the 
phagocyte, occurs through distinct interactions involving ligands on the apoptotic cell, 
receptors on the phagocyte, and bridging molecules which facilitate the interaction 
between receptors and ligands. Ligands expressed by the apoptotic cells serve as ―eat me‖ 
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signals to differentiate apoptotic cells from neighboring, viable cells. Phosphatidylserine 
exposure is one of the most widely recognized ligands on apoptotic cells earmarking 
them for engulfment
78, 79
. In living cells, phosphatidylserine is located on the inside of the 
plasma membrane, and upon apoptosis becomes exposed on the cell surface. 
phosphatidylserine exposure is an early event in apoptosis, and it is estimated that the 
concentration of phosphatidylserine on the cell surface increases greater than 280-fold 
within a few hours of the onset of apoptosis
80
. In addition, annexin I and calreticulin are 
also localized to the inside of viable cells and become exposed during apoptosis. Other 
ligands expressed by apoptotic cells include thrombospondin, ICAM3, oxLDL, C1q, and 
altered sugar moieties. These ligands are either recognized directly by receptors 
expressed by the phagocyte, such as CD36, CD14, scavenger receptors, integrins, and 
lectins, or are coupled to receptors on the phagocyte via bringing molecules, as reviewed 
by others
77, 81, 82
. Two well-studied bringing molecules involved in recognition of 
apoptotic cells are Gas-6, which couples phosphatidylserine exposure to the Tyro-Axl-
Mer family of receptor tyrosine kinases, and milk fat globule EGF-factor 8 (MFG-E8), 
which serves as a bridge between phosphatidylserine and αv integrins (Figure 2-1). 
 Following recognition of apoptotic cells by phagocytes, the phagocyte undergoes 
changes in its cytoskeleton to internalize the apoptotic cell. This process occurs primarily 
through activation of Rac GTPase, though additional mediators may exist. Rac activation 
occurs through at least two different pathways—one being activation of the CrkII-
Dock180-ELMO pathway downstream of apoptotic cell recognition by integrins and 






Figure 2-1. Apoptotic cell “eat me” signals and phagocytic receptors. (From 
Hochreiter-Hufford A and Ravichandran KS, Cold Spring Harbor Perspectives in 
Biology, 2013) 
 
addition, the autophagy pathway is also implicated in Rac activation in phagocytic 
mammary epithelial cells during postpartum involution. Allelic deletion of Becn1 or 
mammary epithelial cell-specific deletion of Atg7, both regulators of autophagy, results 
in defective apoptotic cell clearance within mammary alveoli during involution
83
. While 
Atg does have known roles in phosphatidylserine exposure on apoptotic cells, 
phosphatidylserine exposure by apoptotic mammary epithelial cells following Becn1 and 
Atg knockdown was normal
83
. In vitro analysis of Atg7-deficient primary mammary 
epithelial cells demonstrated the defect in apoptotic cell engulfment was due to decreased 
RAC1 activation, a critical component of the engulfment pathway
83
. Bcln1, Atg5, and 
Atg7 have also been implicated in acquisition of phagocytic ability in macrophages
84
, 
further supporting a role for the autophagy pathway in contributing to apoptotic cell 
engulfment by phagocytic mammary epithelial cells. 
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Apoptotic Cell Clearance Promotes an Immunosuppressive Microenvironment 
 Clearance of apoptotic cells is regarded as a non-immunogenic and non-
inflammatory process, with aspects of active immune suppression. Lack of immune 
activation is considered a cardinal feature of apoptotic cell clearance, and is in contrast to 
necrotic cell clearance which is generally pro-inflammatory
85-87
. In vitro, apoptotic cell 
clearance inhibits the production of pro-inflammatory mediators TNFα, IL-1β, IL-8, IL-
12, and GM-CSF by lipopolysaccharide (LPS)-stimulated macrophages
88, 89
. The anti-
inflammatory effect of apoptotic cell clearance has been shown to be mediated through 
TGF-β, prostaglandin E2 (PGE2), platelet activating factor (PAF), and IL-10 secretion by 
phagocytes, and is dependent on recognition of phosphatidylserine on the apoptotic cell
89-
93
. Furthermore, there is evidence that apoptotic cells can be anti-inflammatory 
themselves, through the release of IL-10 and TGF-β
94, 95
. In addition to inhibiting pro-
inflammatory cytokine production, ingestion of apoptotic cells results in down-regulation 
of iNOS with a concurrent increase in arg-1 in macrophages
92
. This occurs as a result of 
autocrine and paracrine actions of TGF-β and PGE2, and indicates that efferocytosis 
promotes the alternative activation of macrophages through the release of soluble factors. 
It should be noted that in vivo secretion of pro-inflammatory cytokines such as INF-γ, 
IFN-α/β, IL-6, IL-12, and TNF-α has also been associated with apoptotic cell clearance; 
however, the immune suppressive effects of apoptotic cell clearance are dominant
60, 96
.  
While data to date are limited, initial studies looking at cytokine secretion by 
mammary epithelial cells following engulfment of apoptotic targets is consistent with an 
immunosuppressive role for efferocytic mammary epithelial cells. Stimulation of the 
phosphatidylserine receptor on non-transformed murine mammary HC11 cells or co-
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incubation of HC11 cells with apoptotic Jurkat T cells leads to reduced ability to respond 
to stimulation with LPS
97
. Inclusion of a neutralizing antibody to TGF-β reduced the anti-
inflammatory effects of the apoptotic cells by approximately 50%, indicating TGF-β 
secretion by HC11 cells in response to apoptotic stimuli was, at least in part, promoting 
immunosuppression. In vivo, reduced clearance of apoptotic mammary epithelial cells 
during late involution in MerTK deficient mice is associated with decreased TGF-β1, 
consistent with a possible role for TGF-β-mediated immune suppression by phagocytic 
mammary epithelial cells in vivo
98
.  
Proper clearance of apoptotic cells and the resultant localized immune 
suppression is important in maintaining tissue homeostasis, as defective apoptotic cell 
clearance has been identified as an integral part of the pathogenesis of a number of 
diseases. If apoptotic cells are not cleared quickly enough, the cells progress to secondary 
necrosis which is characterized by a loss of membrane integrity, release of intracellular 
contents into the environment, and inflammation
73
. The inflammation associated with 
progression to secondary necrosis is thought to stimulate autoreactivity against the 
cellular contents released by the cell, leading to autoimmunity. Evidence for defective 
cell clearance as an inciting factor in autoimmune diseases comes from mouse models in 
which defects in phosphatidylserine-mediated apoptotic cell recognition associate with 
increased autoantibodies and symptoms consistent with glomerulonephritis and lupus
99-
102
. Furthermore, there is also a strong association between increased apoptotic cells and 
autoimmunity in humans
103, 104
. Defective apoptotic cell clearance has also been 
identified as a prominent factor in diseases of inflammation including chronic obstructive 
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pulmonary disease and atherosclerosis
73
, further emphasizing the importance of efficient 
apoptotic cell clearance and localized immune suppression. 
Phagocytic Mammary Epithelial Cells as Orchestrators of a Tumor-Promotional 
Immune Environment 
The relationship between cancer cells and the immune system is dynamic and 
complex, and in the early conceptualization of this interaction, the cancer 
immunosurveillance hypothesis was proposed. The immunosurveillance hypothesis 
postulates that genetic changes accumulated by cells, which may represent steps toward 
malignancy, serve as antigens for immunologic clearance of the pre-malignant cells
105, 
106
. This hypothesis lost momentum when early studies failed to consistently demonstrate 
a role for the immune system in clearance of cancer cells, and was considered inaccurate 
by 1978
107
. However, in the mid- to late-90s, this hypothesis was revived by experiments 
which were more stringent than those originally performed, and demonstrated that IFN-γ 
and perforin, a mediator of T cell and nature killer cell cytotoxicity, were protective 
against primary tumor formation
108-111
. This work was then followed by subsequent 
studies revealing that tumors could also develop mechanisms to escape surveillance by 




Cancer immunoediting is characterized as occurring in three main phases, 
considered the three E‘s of immunoediting: elimination, equilibrium, and escape
107
. 
During the elimination phase, the immune system functions in immunosurveillance, 
which induces inflammatory signals that attract cells of the innate immune system with 
T-cell activation capabilities. Production of the pro-inflammatory mediators IFN-γ and 
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IL-12 play a large role in elimination of tumor cells by macrophages and nature killer 
cells. The end of the elimination phase is characterized by activation of the adaptive 
immune system and killing of the tumor cells. Following elimination, the tumor enters a 
state of equilibrium with the immune system in which malignant cells are cleared, but not 
quickly enough to completely eliminate the tumor. This results in the emergence of tumor 
cell variants with reduced immunogenicity which are able to evade the immune system. 
Tumors enters the escape phase of immunoediting when these tumor cell variants become 
dominant and expand uncontrollably in the absence of immune elimination
107, 112
.  
In addition to cancerous cells gaining the ability to escape immune surveillance, 
the local immune environment surrounding tumors may also contain immune cell types 
and factors which are directly tumor promotional. In this section I will focus specifically 
on the tumor-promotional effects of macrophages in breast cancer. In breast cancer 
patients, increased macrophage infiltration into primary tumors correlates with tumor cell 
proliferation and significant decreases in relapse-free and overall survival
114-118
. 
Additionally, high levels of the macrophage chemoattractant and growth factor colony 
stimulating factor 1 (CSF-1) and the chemoattractant MCP-1 are associated with breast 
cancer metastasis and poorer outcomes
119, 120
. Direct evidence supporting a role for 
macrophages in breast cancer progression is provided by mouse models in which 
macrophage depletion through CSF-1 knockout significantly decreases tumor progression 
and metastasis, while conversely, overexpression of CSF-1 resulted in increased 
macrophage infiltration in primary tumors and elevated rates of metastasis 
121
. These data 
strongly implicate macrophages in breast cancer progression. Macrophages have been 
shown to promote metastasis through increased extracellular matrix breakdown and 
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remodeling, and angiogenesis, as well as increased tumor cell motility and invasion into 
blood vessels
28, 122
. Additionally, a synergistic paracrine loop has been identified between 
tumor cells and macrophages within mouse mammary tumors, leading to the promotion 
of tumor cell migration. In this dual paracrine signaling event, macrophages produce 
epidermal growth factor (EGF) while tumor cells express the EGF receptor (EGFR), and 
tumor cells produce the CSF-1, which promotes macrophage differentiation and survival 
through CSF-1 receptor expression by macrophages
123
. In support of a similar synergistic 
effect occurring in breast cancer patients, macrophages isolated from breast tumors 
produce EGF, and tumors with high EGFR expression have a higher level of macrophage 
infiltration
124, 125
. Lastly, tumor-associated macrophages are key players in local immune 
suppression within the local environment of tumors. Through secretion of 
immunosuppressive cytokines such as IL-10 and TGF-β, as well as expression of 
arginase-1, tumor-associated macrophages shut down the immune system by effectively 
shutting down the anti-tumor T cell and dendritic cell responses
126, 127
.  
Of direct relevance to my thesis work, nearly all pro-tumorigenic properties of 
tumor-associated macrophages are known properties of phagocytes activated by 
interaction with apoptotic cells, including anti-inflammatory effects/immune suppression 
and production of growth factors and angiogenic factors
128
. It has been proposed that 
apoptotic cell clearance contributes to a tumor-promotional microenvironment through 
recruitment of tumor-associated macrophages, direct stimulation of the tumor cells 
themselves, and suppression of the anti-tumor immune response
128
. Because mammary 
epithelial cells are the primary efferocyte during involution, we propose a similar role for 
phagocytic mammary epithelial cells in orchestrating a tumor-promotional environment 
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in the involuting mammary gland. We predict that upon engulfment of apoptotic cells, 
mammary epithelial cells release chemokines and cytokines, which recruit macrophages 
into the involuting gland and promote alternatively activated macrophages that contribute 
to tumor promotion directly and through suppression of the anti-tumor immune 
response
129
. Indolent tumor cells present in the gland during this time are anticipated to 
both escape immune surveillance and directly be promoted by this environment, possibly 
contributing to local invasion and increased metastasis observed in postpartum breast 
cancer patients and pre-clinical models (Figure 2-2). Additionally, we predict that the 
similarities between phagocytic mammary epithelial cells and professional phagocytes 
are not limited to simply the ability to engulf apoptotic cells, rather we anticipate 
efferocytic epithelial cells themselves will also share many properties of tumor-associated 
macrophages. These may include promotion of angiogenesis, secretion of growth factors, 
and the secretion of cytokines and other factors which promote immune tolerance 
directly, rather than through macrophages as an intermediate. 
Hypothesis and Aims 
 We hypothesize that phagocytic mammary epithelial cells secrete chemokines and 
cytokines that contribute to an alternatively activated macrophage phenotype and tumor-
promotional microenvironment in the postpartum involuting mammary gland. The goals 
of this work are to develop a model to investigate the regulation of the phagocytic 
phenotype in mammary epithelial cells and determine if they secrete chemokines and 
cytokines consistent with tumor-promotion and immune suppression. Through the 
following aims, we anticipate the identification of potential targets for prevention of 
breast cancers that arise in the postpartum setting. 
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 Aim 1.Characterize the phagocytic phenotype of mammary epithelial cells in vivo 
and in vitro. 
 Aim 2. Determine if phagocytic mammary epithelial cells of the involuting gland 
produce chemokines and cytokines involved in the alternative activation of 
macrophages, thus mediating the macrophage phenotype during involution. 
 Aim 3. Characterize COX-2 expression by mammary epithelial cells as a potential 
target for postpartum breast cancer prevention. 
 
Figure 2-2. Model of pro-tumorigenic immune modulation by phagocytic mammary 
epithelial cells. Upon weaning, milk-producing mammary epithelial cells undergo 
apoptosis (dark blue cells) and are extruded into the alveolar lumen. Other milk-
producing mammary epithelial cells transition to become phagocytic (light blue cells) and 
engulf the shed apoptotic cells. Clearance of apoptotic cells is predicted to result in 
release of Th2-like cytokines and growth factors from the phagocytic mammary epithelial 
cells. This cytokine milieu is anticipated to promote alternative activation of 
macrophages (Mφ) and inhibition of cytotoxic T cells (CTL), resulting in an 
immunosuppressed, tumor-supportive microenvironment (green cells). Figure re-printed 
with permission from Landes Bioscience (Fornetti J, Martinson H, Borges VF, Schedin P. 
Emerging Targets for the Prevention of Pregnancy Associated Breast Cancer. Cell Cycle. 





A NOVEL IN VITRO MODEL OF PHAGOCYTIC MAMMARY  
EPITHELIAL CELLS 
Introduction 
Proper clearance of apoptotic cells by the phagocytic mammary epithelium is 
essential during involution, as impaired apoptotic cell clearance can have negative 
consequences on the postpartum mammary gland. For example, persistence of apoptotic 
cells during postpartum involution is associated with increased macrophage infiltration, 
collagen deposition, and vascularization, which persist through at least 60 days post-
weaning
83, 98, 130
. Furthermore, decreased apoptotic cell clearance also leads to increased 
proliferation of the mammary epithelium
98
. These stromal changes and hyperproliferative 
epithelium are similar to the changes observed with ductal carincoma in situ of the breast, 
leading to the speculation that defective apoptotic cell clearance may provide a catalyst 
for breast cancer development
131-135
. In addition, defects in apoptotic cell clearance also 
have negative consequences on future pregnancies. In mice, accumulation of apoptotic 
cells is associated with dilation of the ducts that progressively worsens with additional 
pregnancies, as well as a reduction in the synthesis of the milk proteins
83, 136
. While these 
data provide increasing evidence that efferocytosis by mammary epithelial cells plays a 
crucial role in maintaining tissue homeostasis in the involuting mammary gland, the 
question of whether efferocytosis itself contributes to breast cancer risk is unknown. 
Further, little is known about how mammary epithelial cells switch from a predominantly 
secretory phenotype during lactation to function as the primary phagocyte during 
postpartum involution. 
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One of the key changes in the mammary epithelium that we anticipate playing a 
role in mammary epithelial cells becoming phagocytic during the transition from 
lactation to involution is reorganization of the cell-cell junctions. Given that professional 
phagocytes, such as macrophages, do not exist in monolayers with cell-cell junctions, we 
speculate that changes in the epithelial cell junctions at the onset of involution may be 
necessary in order for mammary epithelial cells to acquire a phagocytic phenotype. The 
most apical of cell-cell junctions are tight junctions, which establish permeability of the 
epithelium, as well as contribute to polarity. Structurally, tight junctions are composed of 
two transmembrane proteins, claudins and occludins, which interact between neighboring 
cells, as well as scaffolding proteins that connect the intracellular portions of claudins and 
occludins to the actin cytoskeleton
137, 138
 (Figure 3-1A). Tracer studies utilizing up-the-
teat injections of [14C]sucrose or FITC-albumin demonstrate rapid closure of the tight 
junctions upon the onset of lactation, resulting in impermeability of the mammary 
epithelium
139-141
. Additionally, electrical potential measurements across the mammary 
epithelium, which are inversely proportionate to permeability, are essentially zero during 
late pregnancy and increase to 20 mV and 37 mV during lactation in goats and mice, 
respectively, further indicating a closing of the tight junctions during lactation
139, 142
. On a 
structural level, this decrease in permeability is associated with increased tight junction 
organization, as visualized by a concentration of claudins and occludins into a tight band 
at the apical lateral membrane
143
. Closure of epithelial tight junctions during lactation is 
necessary for milk production and is driven by progesterone withdrawal coupled with a 
requirement for corticosterone and placental lactogen
144
. Upon milk stasis and during 
postpartum involution, the mammary epithelial tight junctions lose the high degree of 
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impermeability that is characteristic of lactation and become leaky
141
. In addition to 
losing impermeability of the tight junctions, reorganization of adherens junctions is also 
reported to occur upon the switch from lactation to involution. Adherens junctions are 
located immediately below the tight junctions and, as their name implies, function in cell-
cell adhesion. The core of the adherens junction complex is classically composed of the 
transmembrane protein E-cadherin, which anchors to the actin cytoskeleton via a 
complex of p120 catenin, β-catenin, and α-catenin (Figure 3-1B). Cell adhesion is 
mediated by calcium-dependent interactions between the extracellular portions of E-
cadherin on neighboring cells
137, 138
. In mice, truncation of E-cadherin is observed at 3 
days post-wean, leading to release of the β-catenin binding domain
145
. Given that 
engulfment of target particles is dependent on remodeling of the actin cytoskeleton
82
, 
changes in adherens junctions may be particularly relevant to the acquisition of a 
phagocytic phenotype in mammary epithelial cells. Altogether, these data suggest that 
changes in epithelial cell junctions are an important component of the switch from 
lactation to involution.  
One candidate cytokine for inducing junctional reorganization and a phagocytic 
phenotypic in mammary epithelial cells is transforming growth factor β (TGF-β). TGF-β 
belongs to a large superfamily of ligands, which contains over thirty known members 
activins, NODAL, bone morphogenic proteins (BMPs), growth and differentiation factors 
(GDFs), and anti-Mullerian hormone
146
. TGF-β is synthesized as a homodimeric 
proprotein, which contains the propeptide known as latency associated peptide (LAP) and 
mature TGF-β. Within the cell, furin cleaves the proprotein to separate LAP from mature 
TGF-β; however, following cleavage, LAP remains non-covalently associated with TGF-
28 
β. This LAP-TGF-β complex renders TGF-β inactive, and is known as the small latent 
complex. In the endoplasmic reticulum, the small latex complex binds a latent TGF-β 
binding protein (LTBP), through interactions between LTBP and LAP. This leads to the 
formation of the large latent complex, which is secreted from the cell. In the extracellular 
environment, the large latent complex is primarily found tethered to the extracellular 
matrix until TGF-β is activated
147, 148
. Activation of TGF-β from the extracellular matrix 
can occur through the activity of proteases such as thrombospondin, MMP2, and MMP9, 




Once activated, TGF-β binds to the TGF-β type II receptor (TβRII) and induces 
canonical TGF-β signaling through activation of the TGF-β type I receptor, receptor-
associated smads (Smad2/3), and Smad4. In mammals, three different TGF-β isoforms 
exists—TGF-β1, TGF-β2, and TGF-β3—which have approximately 70% sequence 
homology
150
. The TGF-β isoforms have distinct roles in embryonic development, as 
evidenced by the phenotypes of the isoform knockouts. TGF-β1 knockout mice 
experience excessive inflammation and massive immune cell infiltrate into the organs 
which beings during the first week of life
152, 153
. Additionally, these mice have defective 
palatogenesis and pulmonary maturation, and die within four weeks of birth
152, 153
. TGF-
β2 knockout mice have decreased viability in utero with two thirds of fetuses dying 
before or during birth
154
. The mice that survive parturition die within minutes of being 
born due to congenital heart defects and severe skeletal malformations
155
. In TGF-β3 
knockout mice, there is a failure of secondary palate fusion and mice die within twenty 
hours of birth due to pulmonary defects
156, 157
. While the different phenotypes of TGF-β 
29 
knockout mice are likely primarily driven by differences in temporal and spatial 
expression
158
, differential effects of the isoforms have also been reported. For example, in 
a murine model of allergin-induced lung inflammation, TGF-β1 regulated decorin 
deposition and monocyte/macrophage recruitment while TGF-β2 did not
159
. Additionally, 
TGF-β1, 2, and 3 are also reported to be differentially potent in inhibiting lung epithelial 






Figure 3-1. Schematic of tight and adherens junctions. A) Tight junctions are 
composed of junctional adhesion molecules (JAMs), claudins, and occludins, which are 
transmembrane proteins that interact on neighboring cells. The zonula occludens (ZO) 
proteins link the transmembrane proteins to the actin cytoskeleton. B) In adherens 
junctions, the extracellular domains of E-cadherin on neighboring cells interact in a 
calcium dependent manner. p120 catenin, α-catenin, and β-catenin form a complex with 
the intracellular domain of E-cadherin and anchor it to the cytoskeleton. From Niessen 
CM, Journal of Investigative Dermatology, 2007. 
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TGF-β is significantly increased in the mammary gland upon the switch from 
lactation to involution, through at least 9 days post-weaning
161, 162
. TGF-β3 increases the 
greatest upon the lactation to involution switch
37, 57, 161, 162
. Experiments specifically 
overexpressing TGF-β3 or depleting Smad3 or TβRII in the mammary epithelium reveal 
a role for TGF-β in promoting apoptosis during early involution; however, the sustained 
increase in TGF-β expression throughout the postpartum involution window suggests 
roles for TGF-β that extend beyond apoptosis induction
37, 161, 163-166
. Other potential roles 
for TGF-β during involution include influencing the extracellular matrix and immune cell 
composition of the involuting mammary gland
150
, and, importantly for the work 
described here, promoting apoptotic cell clearance by phagocytic mammary epithelial 
cells. TGF-β has been shown to increase the phagocytic capacity of multiple different cell 
types including epithelial cells, fibroblasts, and macrophages
167-171
. In epithelial cells 
specifically, treatment of the retinal pigment epithelium with both TGF-β1 and TGF-β2 
results in increased engulfment compared to untreated controls
167, 171
. Additionally, TGF-
β is implicated in disrupting tight junctions in the mammary gland and has known roles in 
adherens junction dissasembly, making it an intriguing target to investigate in the 
promotion of a phagocytic phenotype in mammary epithelial cells
141, 172, 173
. 
Here, we utilize a novel in vitro model to investigate the role of TGF-β3 in the 
disruption of cell junctions and promotion of a phagocytic phenotype in non-transformed 
murine mammary epithelial cells. We demonstrate that TGF-β3 induces phagocytosis in 
murine mammary epithelial cells, and identify a potential role for changes in adherens 
junctions in the acquisition of a phagocytic phenotype. Furthermore, we identify a 
previously unreported role for the intramembrane protease γ-secretase in the promotion 
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of phagocytosis by TGF-β. In light of the negative consequences of impaired apoptotic 
cell clearance during postpartum involution
83, 98
, our data provide important insight into 
how mammary epithelial cells obtain the phagocytic capacity to clear the gland of the 
immense number of apoptotic cells that are generated during this time. 
Materials and Methods 
Human Tissue Acquisition 
 Under protocols approved by the University of Colorado Institutional Review 
Board, 53 breast tissue specimens were obtained from premenopausal women ages 21 to 
45 years who underwent clinically indicated biopsy (n=2) or surgery (n=51). 
Histologically normal tissue was identified by pathologic review. Based on patient 
histories, cases were stratified into the following reproductive categories: nulliparous 
(n=7), pregnant (n=3), less than or equal to 1 month post-lactation (n=6), greater than 1 
month and less than or equal to 6 months postpartum (n=6), greater than 6 months and 
less than or equal to 12 months postpartum (n=4), greater than 12 months and less than or 
equal to 18 months postpartum (n=2), greater than 18 months and less than or equal to 24 
months postpartum (n=7), greater than 24 months and less than or equal to 3 years 
postpartum (n=4), greater than 3 years and less than or equal to 6 years postpartum (n=8), 
and greater than 6 years postpartum (n=6).  
Animal Husbandry, Reproductive Staging, and Tissue Preparation 
 Animal procedures were approved by the University of Colorado Anschutz 
Medical Campus Institutional Care and Use Committee. Rats were bred, normalized to 6 
pups per liter on involution day 2, and mammary tissue harvested at the following 
reproductive stages, as described
174
: age-matched virgin; pregnant (days 18-20); lactation 
32 
(days 10-11); involution day 2, 4, 6, 8, and 10 (2-10 days post-wean); and fully regressed 
(4 weeks post-wean). 
Immunohistochemical (IHC) and TUNEL Staining, Image Acquisition, and 
Quantification of Breast and Mammary Tissues  
For human and rodent tissue, 4 µm thick formalin-fixed, paraffin-embedded 
sections were deparaffinized and rehydrated. For IHC staining except p-Smad2, sections 
were subjected to antigen retrieval (125
o
C under pressure for 5 minutes), and sequentially 
incubated in 3% H2O2 block (room temperature (RT), 5 mins), Protein Block (RT, 10 
mins; Dako, Carpinteria, CA), primary antibody (RT, 1 hour), secondary antibody (RT, 
30 mins), 3,3‘-diaminobenzidine (RT, 10 mins; Dako, Carpinteria, CA), and hematoxylin 
(RT, 6 mins; Dako, Carpinteria, CA). See Table 3-1 for specific antigen retrieval and 
antibody information. p-Smad2 staining was performed as described
154
. For dual E-
cadherin and TUNEL staining of rat tissue, E-cadherin IHC was performed followed by 
TUNEL staining using the TACS 2 TdT-Fluor In Situ Apoptosis Detection Kit (Trevigen, 
Gaithersburg, MD) with the Mn
2+
 cation at a final concentration of 1x per manufactures 
instructions. Fluorescent images were acquired using an Olympus IX81 inverted 
microscope and Slidebook v.4.067 software (Intelligent Imaging Innovations, Denver, 
CO). Images of mannose receptor (MR) stained tissue were achieved by extracting 
regions from whole-slide images that were acquired using a ScanScope T3 scanner at 
0.46 µ per pixel. Due to heterogeneous MR expression in the alveolar epithelium across a 
single case, quantification of MR expression by mammary epithelial cells was performed 
by determining whether or not each case had any MR positive mammary alveoli. In cases 
without MR staining in the mammary epithelial cells, evidence that the staining worked 
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was provided by identifying positive stromal cells. For E-cadherin, β-catenin, and p-
Smad2, light microscopy images were acquired using a Zeiss Axioskop and Spot RT3 
camera. Quantification of nuclear β-catenin was performed by counting the total number 
of epithelial nuclei and determining the percentage that were β-catenin positive. The 
lymph node region of the fourth right mammary gland was analyzed from four rats per 
stage, with five representative fields analyzed per rat. In total, approximately 23,400 
nuclei were quantified from 18 mammary glands (3900 nuclei per stage). 
 
Table 3-1. Specific pre-treatment and antibody information for IHC staining of 
human and rat tissue.  
Antigen Pre-treatment Primary Antibody Secondary Antibody 




Dako Envision Plus Mouse 
Cleaved caspase-





Molecular Probes goat anti-









Molecular Probes goat anti-




Dako TRS Cell Signaling 
#3195, 1:100 
Dako Envision Plus Rabbit 
E-cadherin, rat 
(dual stain with 
TUNEL) 




Molecular Probes goat anti-
mouse AF594, #11032 
E-cadherin, rat 
(single stain) 
Dako TRS BD Biosciences 
#610181, 1:500 
Dako Envision Plus Mouse 
Mannose 
receptor, human 
Dako TRS Sigma 
#HPA004114, 1:600 
Dako Envision Plus Rabbit 
 
In Vitro Phagocytosis Assay 
 Non-transformed, murine mammary EpH4 cells were cultured in DMEM high 
glucose (Sigma-Aldrich, St. Louis, MO), without L-glutamine or sodium pyruvate, with 
additives at the following final concentrations: 5% FBS, 2 mM L-glutamine, 10 mM 
HEPES, and 100 units/ml each of penicillin and streptomycin (all additives from 
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Hyclone, Logan, UT). In order to promote junctional integrity prior to use in 
phagocytosis assays, cells were maintained as confluent monolayers split 1:3 every 5-7 
days with daily media changes. For phagocytosis assays, 70,000 EpH4 cells were plated 
in complete medium onto 0.4 µm filters (BD Biosciences, San Jose, CA) in a 24-well 
format with the media changed daily. Cells were allowed to form a monolayer with intact 
cell junctions. To monitor integrity of cell junctions, the transepithelial electrical 
resistance (TER) was measured daily, prior to changing the media. Once the TER 
reached 300 Ω*cm
2
, complete medium was removed, cells were washed twice with PBS, 
and then treated with 1, 3, or 5 ng/ml recombinant human (rh) TGF-β3; 20 or 40 mM 
LiCl; 50 or 200 ng/ml Wnt3a, or vehicle in serum-free medium for 24 hours. For 
inhibition studies, cells were treated with 500 nM L-685,458, 20 µM DAPT, or 25 µM 
iCRT3 simultaneously with 1 ng/ml TGF-β3. TGF-β3, Wnt3a, and DAPT were 
purchased from R&D Systems (Minneapolis, MN), and LiCl, L-685,458, and iCRT3 
from Sigma-Aldrich (St. Louis, MO). After 24 hours, medium containing the treatment 
was removed, cells were washed twice with PBS, and monolayers were incubated with 
10 µm Fluoresbrite BB carboxylated latex microspheres/beads (Polysciences, Inc., 
Warrington, PA) for 4-6 hours. Following incubation, cells were washed three times with 
ice cold PBS to remove un-engulfed beads. EpH4 cell monolayers contain similar cell 
numbers across treatment conditions (data not shown); therefore, phagocytic index was 
quantified by multiplying the number of phagocytes by the average number of targets 
engulfed per phagocyte. Because the monolayers contain an equivalent number of cells 
across conditions, this calculation yields the same relative changes in phagocytosis across 
conditions as multiplying the percent of cells that are phagocytic by the average number 
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of targets engulfed per phagocyte. Results are reported as fold change compared to 
vehicle treatment due to variation in baseline phagocytosis levels across experiments.  
Immunocytochemistry of Mammary Epithelial Cells in Culture 
 EpH4 cell monolayers on transwell filters were fixed in 4% paraformaldehyde for 
15 minutes and permeabilized using 0.5% Triton-X100 (Sigma-Aldrich). Fixed cells on 
filters were then incubated sequentially at RT with 1.1M glycine for 5 minutes to quench 
autofluorescence, 20 mg/ml BSA for 1 hour to block non-specific protein interactions, 
and with primary and secondary antibodies (Table 3-2) for 60 minutes and 30 minutes, 
respectively. Filters were then removed from transwells with a scalpel and mounted onto 
slides using Prolong® Gold Antifade Reagent with DAPI (Life Technologies, Grand 
Island, NY). 
 
Table 3-2. Primary and secondary antibody information for immunocytochemistry 
of mammary epithelial cells in culture. 
Antigen Primary Antibody Secondary Antibody 
E-cadherin BD Biosciences 
#610181, 1:100 
Molecular Probes #44094 
Goat-anti-mouse Alexa Fluor® 488, 
1:1000  
ZO-1 Santa Cruz  
sc-33725, 1:100 
Molecular Probes #A11081 
Goat-anti-rat Alexa Fluor® 546, 1:1000  
Cleaved caspase-3 Cell Signaling #9661, 
1:100 
Molecular Probes #11032 
Goat-anti-mouse Alexa Fluor® 594, 
1:1000  
 
γ-secretase Activity Assay 
For measurement of γ-secretase activity in mammary gland tissue lysates, 
pulverized frozen mammary tissue with the lymph node removed from lactation and 
involution days 2-6 was homogenized in 400 µl of assay buffer (50 mM Tris-HCl, pH6.8; 
2 mM EDTA; 0.25% CHAPSO). Protein concentrations were determined using Bio-Rad 
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Protein Assay Dye Reagent. 10 µg of total protein and 8 µm fluorogenic γ-secretase 
substrate (Calbiochem, EMD Millipore, Billerica, MA) were incubated in assay buffer in 
a final reaction volume of 150 μl for 5 hours at 37
o
C. After incubation, reactions were 
centrifuged at 16,100g for 15 minutes at 4
o
C. Supernatant was transferred to a black-
walled 96-well plate (ThermoScientific, Waltham, MA) and fluorescence was measured 
at an excitation wavelength of 360/40 nm and emission wavelength of 460/40 nm using a 
BioTek Synergy 2 (Winooski, VT). To account for differences in cellular content in 
mammary tissue from lactation to involution day 6, fluorescence was normalized to actin 
level in homogenized mammary tissue samples as determined by immunoblot. For 
immunoblotting, 20 μg of mammary tissue lysate homogenized in γ-secretase activity 
assay buffer was separated by SDS-PAGE using a 10% acrylamide gel. Immunoblotting 
using mouse-anti-actin (EMD Millipore, Billerica, MA; 1 hour, RT) and densitometry 
were performed as described below. 
To assess γ-secretase activity in the in vitro studies, medium was removed from 
treated EpH4 cell monolayers grown on filters, cells were washed twice with ice cold 
PBS, and harvested directly into 50 µl assay buffer. 25 µg of lysate was combined with 8 
µm (final concentration) substrate in a final reaction volume of 150 µl assay buffer. 
Reactions were incubated for 8 hours at 37
o
C, and fluorescence was measured as 
described above. 
Immunoblotting and Quantification 
 Pooled rat mammary tissue lysates were prepared as described (n=6 
animals/reproductive group)
56
. EpH4 cell lysates were prepared by harvesting cells 
directly into 100 μl Radio Immuno Precipitation Assay (RIPA) buffer (10 µM Tris pH 
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7.4, 150 µM NaCl, 0.1% SDS, 1% sodium deoxycholate, and 1% Triton X-100) 
containing protease and phosphatase inhibitors (1x Protease Inhibitor Cocktail (Sigma), 
200 µg/mL PMSF, 1 mM Na3VO4, and 50 mM NaF). For latent TGF-β, samples were run 
under non-reducing conditions by preparing mammary tissue lysate samples in loading 
buffer containing 10% SDS, 50% glycerol, 0.4 M Tris pH 6.8, and 0.1% w/v 
bromophenol blue without reducing agents. Thirty µl of total protein were separated by 
SDS-PAGE using a 10% acrylamide gel. Membranes were blocked in 5% non-fat dry 
milk in TBS-T (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 hour at 
room temperature. Immunoblotting was performed using mouse anti-bovine TGF-β1, 2, 
and 3 (MAB1835, R&D Systems, Minneapolis, MN; overnight, 4
o
C), mouse anti-human 
E-cadherin (610181, BD Biosciences, San Jose, CA; overnight, 4
o
C), rabbit anti-human 
presenilin 1 (ab65293, Abcam, Cambridge, MA), or rabbit anti-mouse GAPDH (G9545, 
Sigma-Aldrich, St. Louis, MO; 1 hour, RT) followed by anti-mouse or anti-rabbit HRP-
conjugated secondary antibody (Santa Cruz Biotechnologies, Santa Cruz, CA and Bio-
Rad Laboratories, Hercules, CA, respectively; 30 minutes, RT) with detection using with 
detection using ECL Western Blotting Substrate (Thermo Fisher Scientific, Waltham, 
MA). Densitometry was performed using Image J Software
175
.  
RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR  
 Two hundred µl TRIzol® Reagent (Life Technologies, Grand Island, NY) were 
added to EpH4 cell monolayers per 24-well transwell filter immediately following 
removal of medium, and samples were harvested using a cell scraper modified to fit 
within the transwell filter. RNA was isolated per manufacturer‘s protocol, and to 
facilitate RNA precipitation, 10 μg UltraPure™ glycogen (Life Technologies, Grand 
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Island, NY) was added per sample during the RNA precipitation. Resultant RNA was 
resuspended in 20 μl nuclease-free water and RNA concentration determined using a 
NanoDrop 2000 UV-Vis Spectrophotometer (ThermoScientific). Reverse transcriptase 
reactions were performed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA) with 1 μg total RNA. For quantitative RT-PCR, 1 μl of reverse 
transcriptase reactions with SYBR green (Bio-Rad Laboratories, Hercules, CA), forward 
and reverse primers at a concentration of 1 μM each, and brought up to a final reaction 
volume of 20 μl with nuclease-free water. The following primers were used, from 
Integrated DNA Technologies (Coralville, Iowa): presenilin-1, forward: 5‘-ACC TGC 
ACC TTT GTC CTA CTT CCA-3‘; presenilin-1, reverse: 5‘-TGT CAA GTC TCT GCC 
TGT CAT GCT-3‘; actin, forward: 5‘-GCA ACG AGC GGT TCC G-3‘; actin, reverse: 
5‘-CCC AAG AAG GAA GGC TGG A-3‘. Reactions were run using the following 
program: 3 min, 95
o
C; 10 sec, 95
o
C, 1 min 60
o
C (42 cycles); 1 min, 95
o
C, 1 min, 55
o
C. 
Primer specificity was confirmed via melt-curve analysis. Data were collected using the 
MyiQ Single Color Real-Time PCR Detection System with iQ5 software (Bio-Rad 
Laboratories), and presenilin-1 gene expression was normalized to actin using the delta-
delta Ct method. 
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism v.6 software, as 
indicated. 
Results 
Using mouse models, epithelial cells have been identified as the primary 




. To determine if apoptotic cell clearance is a conserved function of the 
mammary epithelium during involution across species, immunohistochemistry (IHC) was 
performed using postpartum involuting mammary tissue from human and rat. Dual 
fluorescent staining for apoptotic cell markers (rat=TUNEL, human=cleaved caspase-3) 
and the epithelial cell marker E-cadherin demonstrated frequent apoptotic cells within the 
alveolar mammary epithelium during involution in both the rat and human (Figures 3-2A 
and B),and lack of engulfment in the nulliparous glands (data not shown). These data 
indicate apoptotic cell clearance is a conserved function of mammary epithelial cells 
during postpartum involution across species. In addition, mannose receptor (MR), a 
scavenger receptor involved in engulfment of glycoproteins, as well as opsinization-
independent recognition and engulfment of bacterial, viral, and fungal pathogens
176
 was 
only observed to be expressed by human mammary epithelial cells during involution 
(Figure 3-2C). MR expression by mammary epithelial cells was transient and specific to 
postpartum involution, detectable in 100% of cases within 1 month of lactation cessation, 
66.7% of cases between 1 and 6 months postpartum, and 25% of cases between 6 and 12 
months postpartum, compared to undetectable levels in the nulliparous and fully 
regressed gland (Figure 3-2D). MR expression by mammary epithelial cells during 
postpartum involution raises the intriguing possibility that they phagocytic capacity 
extends beyond that of apoptotic cell engulfment to include clearance of milk 
constituents, with a possible role in host defense; however, functional experiments need 
to be done to test whether MR expression by mammary epithelial cells confers increased 
phagocytic ability.   
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Figure 3-2. Mammary epithelial cells are phagocytic during postpartum involution 
across species. A and B) Apoptotic cells (arrows) engulfed by mammary epithelial cells 
in rat (A) and human (B) mammary tissue. C,D) Mannose receptor (MR) expression (C) 
and quantification (D) in mammary epithelial cells during involution in human breast 
tissue. E-cad=E-cadherin, CC3=cleaved caspase-3, Inv=involution, Nullip=nulliparous. 
 
Based on reported roles for TGF-β in regulating phagocytosis in both professional 
and non-professional phagocytes
167-171
, we hypothesize that TGF-β may play a role in 
increasing the phagocytic capacity of mammary epithelial cells during postpartum 
involution. In mice, TGF-β expression has been well characterized as increasing in 
mammary tissue upon the switch from lactation to involution
37, 57, 161, 162
. To determine if 
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TGF-β is similarly increased in rat mammary tissue, western blotting for latent TGF-β 
was performed using whole mammary tissue lysates. Like mouse, TGF-β increased in rat 
mammary tissue during involution compared to lactation (Figure 3-3A). Because TGF-β 
activity is known to be highly regulated post-transcriptionally, IHC was performed for p-
Smad2 to determine if TGF-β activity increased in mammary epithelial cells during 
involution. Nuclear p-Smad2 staining was very low during lactation and increased 
throughout involution, particularly within the mammary epithelium (Figure 3-3B). These 
data indicate mammary epithelial cells are the primary cell type responding to TGF-β 
during involution, and are consistent with a potential role for TGF-β in promoting a 
phagocytic phenotype in mammary epithelial cells during involution. 
To determine if TGF-β induces phagocytosis in mammary epithelial cells, non-
transformed murine mammary epithelial EpH4 cells were cultured at high density on 
transwell filters, which permits cells to form a polarized monolayer with functional tight 
cell-cell junctions. Mammary epithelial cells with tight cell-cell junctions mimic the state 
of lactation, where tight junctions become highly organized and the epithelium reaches a 
degree of impermeability that is only observed during lactation
144
. In this cell culture 
model, the tightness of the cell junctions can be monitored by measuring the electrical 
resistance across the epithelial cell monolayer, in a measurement known as the 
transepithelial electrical resistance (TER). TER was measured daily to monitor the 
formation of established epithelial cell monolayers with functional tight junctions. Upon 
achieving a TER greater than 300 Ω*cm
2 
as a readout of impermeable tight junctions 
(Figure 3-3D), the monolayers were treated with 1 ng/ml TGF-β3 for 24 hrs. TGF-β3 was 
chosen over TGF-β1 for these studies based on our data (Figure 3-3C) and the work of 
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others
37, 57, 161, 162
 demonstrating its relative abundance over TGF-β1 during early 
involution, and the fact that TGF-β2 appears to be predominantly associated with 
lactation (Figure 3-4). On average, TGF-β3 increased the ability of mammary epithelial 
cells to engulf carboxylated latex beads, a surrogate for apoptotic cells
177, 178
, by 
approximately 4.5-fold compared to untreated cells (Figure 3-3E), and this was further 
enhanced at higher TGF-β3 doses (Figure 3-3F). Importantly, while TGF-β treatment can 
induce apoptosis in non-transformed mammary epithelial cells
37, 179
, apoptosis was not 
observed in EpH4 cell monolayers following 1 ng/ml TGF-β3 treatment (Figure 3-3G). 
Therefore, this lower dose was used for subsequent phagocytosis studies. 
In addition to increasing phagocytic ability of EpH4 mammary epithelial cells, 
TGF-β3-treated monolayers failed to increase their TER over time compared to vehicle-
treated cells (Figure 3-5A). Notably, the extent of phagocytosis induced by TGF-β3 
treatment strongly correlated with the difference in TER between vehicle and TGF-β3-
treated cells (Figure 3-5B). The minimal net change in TER pre- and post-TGF-β3 
treatment (Figure 3-5A) suggests that TGF-β3 either prevents further junctional 
tightening that occurs across time in this model, or induces focal areas of tight junction 
disruption that are offset by the tightening of junctions in other areas of the monolayer. 
Assessment of monolayer integrity using immunofluorescence IF for the tight junction 
protein ZO-1 supports the later, with focal disruption of tight junctions observed 
following TGF-β3 treatment (Figure 3-5C). These tight junction changes following TGF-
β3 treatment recapitulate reported changes in tight junction integrity in vivo upon the 




Figure 3-3. TGF-β3 promotes phagocytosis in EpH4 cell monolayers.   
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Figure 3-3. TGF-β3 promotes phagocytosis in EpH4 cell monolayers. A) Pan-TGF-β 
immunoblot (top) and quantification (bottom) using pooled rat mammary tissue (n=6 
animals/stage) demonstrates increased TGF-β in the mammary gland upon the switch 
from lactation to involution. B) Increased p-Smad2 expression (brown) by mammary 
epithelial cells in the involuting rat mammary gland; dashed line=alveolus; 
white=alveolar lumen; Scale bar=20 µm. C) Quantification of p-Smad2 IHC. D) 
Immunocytochemistry (ICC) for E-cad and ZO-1 in EpH4 cell monolayers prior to 
treatment reveals monolayers with established cell junctions. E) Data from two publically 
available mouse microarray data sets
54, 59
 demonstrate TGF-β3 increases more than TGF-
β1 upon the switch from lactation to involution. F) 1 ng/ml TGF-β3 increases phagocytic 
capacity of EpH4 cell monolayers approximately 4-fold (n=13 experiments). *p<0.05, 
one-sample, two-tailed T test G) Dose-response increase in phagocytosis by EpH4 cells 
following TGF-β3 treatment. *p<0.05, **p<0.01, ***p<0.0001, two-sample, one-tailed T 
test. H) 1 ng/ml TGF-β3 treatment does not induce apoptosis in EpH4 cell monolayers as 




Figure 3-4. TGF-β2 expression in the mammary gland is high during lactation and 
decreases through involution. RNase protection assay (left) and quantification (right) 
for TGFb2 expression in rat mammary tissue lyates. Assay performed by Mark Kaeck in 
the Schedin lab. 
 
during lactation and become leaky during involution
141
. In addition to mimicking the 
tight junction changes associated with involution, TGF-β3 treatment of EpH4 monolayers 
also increased cytoplasmic localization and cleavage of E-cadherin (Figures 3-5C and D). 
Because TGF-β is known to disrupt adherens junctions through the induction of pathways 
involved in epithelial-to-mesenchymal transition (EMT), expression of transcription 
factors involved in EMT and mesenchymal markers were investigated in this model
180
. 
Notably, Snai1, Snai2, Twist1, Twist2, Zeb1, Vim and Fn1, genes highly associated with 
EMT, were not upregulated in EpH4 cell monolayers following TGF-β3 treatment, and in 
fact, Zeb1 was significantly down-regulated following TGF-β3 treatment (Table 3-3). 
These data indicate that the junctional changes in this model are likely not a result of 
TGF-β-induced EMT within the post-lactational mammary epithelium. 
To determine if E-cadherin reorganization in EpH4 mammary epithelial cell 
monolayers following TGF-β3 treatment recapitulates changes occurring in the 
epithelium in vivo during involution, IHC for e-cadherin was performed using rat 




Figure 3-5. Phagocytosis following TGF-β3 treatment is associated with decreased 
junctional integrity. A) Decreased transepithelial electrical resistance (TER) in EpH4 
cell monolayers treated with TGF-β3. *p<0.05, two-sample, two-tailed T test. B) 
Phagocytosis following TGF-β3 treatment correlates with the difference in TER 
compared to vehicle (veh) treatment. C) ZO-1 and E-cadherin (E-cad) are less localized 
at cell-cell junctions in TGF-β3-treated EpH4 cell monolayers. D) Increased E-cad 




Table 3-3. Transcription factors associated with EMT and mesenchymal markers 
are not upregulated following TGF-β3 treatment of EpH4 cell monolayers. 
Gene Fold Change vs. Veh P-value* 
Snai1 -1.08 0.60 
Snai2 -1.02 0.90 
Twist1 1.09 0.80 
Twist2 -1.09 0.61 
Zeb1 -1.45 0.02 
Vim -1.35 0.39 
Fn1 1.02 0.66 
*Two-tailed T Test 
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cycle. Virgin mammary glands exhibit moderate to strong E-cadherin junctional staining, 
which visibly decreased during the period of alveolar expansion associated with 
pregnancy (Figure 3-6A). During lactation, specific localization of E-cadherin to the 
lateral cell junctions was greatest, consistent with known junctional impermeability 
during lactation
144
. Upon the switch from lactation to involution, E-cadherin localized 
away from the lateral cell junctions as demonstrated by apical staining during early 
involution (Figure 3-6A, Inv2 and 4 panels, arrows) , and cytoplasmic staining 
throughout involution (Figure 3-6A, Inv6 panel, asterisk). In human breast tissue, E-
cadherin was similarly well-localized to lateral cell junctions during lactation (Figure 3-
6B, Lac panel) with apical (Figure 3-6B, Inv panel, arrow) and cytoplasmic localization 
(Figure 3-6B, Inv panel, asterisk) evident during involution. These data indicate that 
relocalization of E-cadherin away from lateral epithelial cell junctions is a conserved 
feature of mammary gland involution across species. We also found that the involution-
associated changes in E-cadherin localization were associated with partial proteolysis of 
the protein (Figure 3-6C). Similar to the in vitro studies, transcription factors associated 
with EMT are not upregulated in vivo in publically available data sets
54, 59
 (data not 
shown), further indicating EMT likely does not play a role in the acquisition of a 
phagocytic phenotype by mammary epithelial cells. 
Previously, it has been reported that the β-catenin binding domain of E-cadherin 
is released during early involution
145
. To determine if E-cadherin cleavage associated 
with relocalization of β-catenin away from lateral cell junctions, IHC for β-catenin was 
performed in the rat mammary tissues. Translocation of β-catenin to the nucleus was 
observed as early as day 4 of involution, with nuclear levels peaking at involution day 6 
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(Inv6) (Figures 3-6D). These data are consistent with E-cadherin cleavage during 
involuting resulting in release of β-catenin from the cell membrane, allowing for 
translocation into the nucleus.  
Cleavage of E-cadherin and release of the β-catenin binding domain can occur via 
the intramembrane protease γ-secretase
145
. Utilizing a γ-secretase activity assay, we 
found γ-secretase activity to increase in the mammary gland from lactation to involution 
day 6 (Figure 3-6E). The γ-secretase enzyme complex consists of four known subunits—
nicastrin, anterior pharynx-defective 1, presenilin, and presenilin enhancer 2. Presenilin is 
the catalytic component of the complex, while the other three proteins serve as obligate 
co-factors. There are two presenilin homologs, presenilin 1 and 2, either of which may be 
in the γ-secretase complex, as reviewed previously
181, 182
. Analysis of publically available 
mouse microarray datasets demonstrated that presenilin 1 gene expression increases in 
the mammary gland upon the switch from lactation to involution (Figure 3-6F), 
indicating increased γ-secretase activity in the gland during this time may be a result of 
new protein synthesis. Following TGF-β3 treatment of EpH4 cell monolayers in vitro, 
modest increases were also observed in γ-secretase activity for two out of three 
experiments (Figure 3-6G), and in three out of three experiments we observed increases 
in presenilin 1 gene (Figure 3-6H) and protein (Figure 3-6I and J) expression. For 
presenilin 1 protein, dimers represent stable pools of protein, while the c-terminal 
fragment (CTF) is indicative of activated presenilin 1
183, 184
. Though the in vitro changes 
in γ-secretase activity and presenilin 1 upregulation were small, the repeated increases 
across difference assays is consistent with γ-secretase cleavage of E-cadherin following 
TGF-β3 treatment.  
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In addition to E-cadherin, γ-secretase cleaves many other integral membrane 
proteins, one of which is the transmembrane receptor Notch. Notch signaling is initiated 
upon binding with ligands Delta or Jagged, and is dependent on extracellular cleavage by 
α-secretase followed by intracellular cleavage by γ-secretase. γ-secretase cleavage 
releases the Notch intracellular domain which participates in transcriptional activation, as 
reviewed by Wolfe
185
. Further, activation of the Notch pathway, via Notch cleavage, 
promotes phagocytosis in microglia
186
. Therefore, to investigate whether Notch signaling 
may contribute to acquisition of the phagocytic phenotype in our cell culture model, 
immunoblotting was performed for the active form of Notch, which is cleaved at 
Val1744. Cleavage of Notch was not observed following TGF-β3 treatment, suggesting 
γ-secretase activation of the Notch pathway is likely not involved in the induction of a 
phagocytic phenotype. However, increases in full length Notch and the transmembrane 
region (NTM) were observed (Figure 3-7), so additional experiments are required to 
understand the potential role of Notch in the ‗phagocytic switch‘. 
To determine if γ-secretase activity is required for TGF-β3-induced phagocytosis 
in EpH4 cell monolayers, cells were treated with TGF-β3 in combination with two 
different γ-secretase inhibitors, DAPT and L-685,458. Both inhibitors reduced 
phagocytosis induced by TGF-β3 treatment (Figures 3-8A and B), indicating that γ-
secretase mediates TGF-β3-induces phagocytosis in EpH4 cell monolayers.  
Given that γ-secretase cleavage of E-cadherin leads to release of β-catenin from 
the cell membrane, we next sought to determine whether increased phagocytosis 
following TGF-β3 treatment was β-catenin dependent. Similar to γ-secretase inhibitors,  
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Figure 3-6. Reorganization of adherens junctions and increased γ-secretase activity 
during involution in the rat mammary gland.   
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Figure 3-6. Reorganization of adherens junctions and increased γ-secretase activity 
during involution in the rat mammary gland. A,B) IHC for E-cadherin using rat (A) 
and human (B) mammary tissue. Arrow=apical localization, asterisk=cytoplasmic 
localization. C) Western blotting for E-cadherin using pooled rat mammary tissue lysate 
(n=6 animals/stage); FL=full length; CTF=C-terminal fragment. D) β-catenin IHC stain 




p<0.01 two-sample, two-tailed T test compared to lactation. E) Presenilin-1 
(Psen1) gene expression increasing in the murine mammary gland upon the switch from 
lactation to involution in two publically available microarray data sets. F) Increased γ-
secretase activity in rat mammary glands during postpartum involution. G) γ-secretase 
activity increased in two out of three experiments following TGF-β3 treatment. H) 
Increaesd presenilin 1 gene (PSEN1) expression in EpH4 cell monolayers following 
TGF-β3 treatment, *p<0.05, two-tailed two-sample T test. I and J) Quantification (I) and 
immunoblot (J) for presenilin 1 in EpH4 cell monolayers treated with TGF-β3, *p<0.05, 




Figure 3-7. Notch cleavage is not observed in EpH4 cell monolayers following TGF-
β3 treatment. Immunoblot (left) and quantification (right) for cleaved Notch, full-length 
Notch, and the transmembrane region of Notch (Notch-NTM). 
 
 
β-catenin inhibition decreased TGF-β3-induced phagocytosis by EpH4 cell monolayers 
(Figure 3-8C). Together, these data demonstrate TGF-β3 induces phagocytosis in EpH4 
cells through γ-secretase and β-catenin-dependent mechanisms. We next investigated 
whether induction of β-catenin signaling is able to induce phagocytosis in EpH4 cell 
monolayers. Activation of β-catenin signaling by LiCl treatment (Figure 3-8D) was not 
sufficient to induce phagocytosis (Figure 3-8E). These data suggest pathways in addition 
to β-catenin may be required for induction of phagocytosis by TGF-β3; however, LiCl is 
a non-specific activator of β-catenin so additional LiCl targets cannot be ruled out as 
having an inhibitory effect on phagocytosis. Next, the role of β-catenin in promoting 
phagocytosis was further explored by activating the canonical Wnt signaling pathway, 
which is a well-known means of activating β-catenin
187
. To this end, EpH4 cell 
monolayers were treated with Wnt3a, a known inducer of canonical Wnt signaling. 
Following Wnt3a treatment, there was only minimal change in expression of β-catenin 
target genes Axin2 and Tcf7 (Figure 3-8F), indicating that EpH4 cells do not respond 
robustly to canonical Wnt signaling in this model. Altogether, these data support a model  
  
53 
for Wnt-independent β-catenin signaling in the induction of phagocytosis in mammary 
epithelial cells; a model in which γ-secretase cleavage of E-cadherin results in release of 
β-catenin from the cell membrane and subsequent translocation into the nucleus where it 
activates genes necessary for the induction of phagocytosis in mammary epithelial cell 





Figure 3-8. TGF-β3 induces phagocytosis in EpH4 cell monolayers through γ-
secretase and β-catenin. A-C) Treatment with the γ-secretase inhibitors DAPT (A) and 
L-685,458 (B), or the β-catenin inhibitor iCRT3 (C) reduces TGF-β3-induced 
phagocytosis. a-d) Two-tailed, two-sample T test, p<0.05 when compared to vehicle (a), 
TGF-β3 (b), TGF-β3+DMSO (c), and TGF-β3+γ-secretase inhibitor; *p,0.05, two-tailed, 
one-sample T-test. D) qRT-PCR demonstrates increased expression of β-catenin target 
genes by EpH4 cell monolayers following LiCl treatment. E) LiCl treatment does not 
induce phagocytosis in EpH4 cell monolayers (representative of 2 experiments). 
#
p<0.05 
compared to vehicle, two-tailed, two-sample T test. F) EpH4 cell monolayers respond 
weakly toWnt3a treatment, suggesting minimal response to canonical Wnt signaling. 







Figure 3-9. Proposed model of phagocytosis induction in mammary epithelial cells 
following TGF-β3 treatment. Following TGF-β3 treatment, γ-secretase activity cleaves 
the intracellular portion of E-cadherin, releasing β-catenin from the cell membrane. β-




 Deficiencies in apoptotic cell clearance during postpartum mammary gland 
involution have negative consequences on tissue architecture and function
83, 98, 130
. Upon 
the cessation of lactation, mammary epithelial cells lose their secretory phenotype, and—
somewhat surprisingly—acquire phagocytic properties to function as the primary cell 
responsible for apoptotic cell clearance during postpartum involution. Currently, little is 
known about how mammary epithelial cells obtain the phagocytic capacity to clear the 
gland of the immense number of apoptotic cells generated during involution
76, 98
. Here, 
we describe a novel in vitro model for studying the induction of a phagocytic phenotype 
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in mammary epithelial cells that utilizes long-term culture on transwell filters to permit 
the maturation of a polarized epithelium with impermeable tight junctions similar to those 
normally found in the mammary gland only during lactation
139, 141, 144
. TGF-β3 treatment 
in this model induces phagocytosis and recapitulates multiple aspects of the lactation to 
involution switch, including loss of tight and adherens junction integrity in an epithelial 
cell monolayer with previously established cell junctions. Our data unveil a previously 
undescribed role for TGF-β3 in the induction of a phagocytic phenotype in mammary 
epithelial cells, through γ-secretase and β-catenin. Furthermore, using clinical samples, 
we demonstrate that human breast epithelial cells function in apoptotic cell clearance 
during involution, and provide evidence through MR staining that their phagocytic 
capacity likely includes milk resorption. 
 Based on our in vivo and in vitro data, we predict that upon the switch from 
lactation to involution, TGF-β3 induces γ-secretase activity, leading to E-cadherin 
cleavage, release of β-catenin from the cell membrane, translocation of β-catenin into the 
nucleus, and increased transcription of genes involved in phagocytosis. In support of this 
model and consistent with our results, TGF-β has been shown by others to increase 
expression levels and activity of presenilin 1, the catalytic component of the γ-secretase 
complex, in prostate cancer cells through polyubiquitination
188
. Presenilin 1 can effect β-
catenin transcriptional activity through mechanisms that are dependent or independent of 
γ-secretase enzyme activity
189
. Our data demonstrating that two different γ-secretase 
inhibitors were able to reduce TGF-β3-induced phagocytosis indicate a role for γ-
secretase-dependent regulation of β-catenin. Furthermore, increased γ-secretase activity 
following TGF-β3 treatment further supports a role for γ-secretase-dependent regulation 
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of β-catenin. In addition to γ-secretase-dependent and –independent effects of presenilin 
1 on β-catenin, presenilin 1 also both positively and negatively regulates β-catenin 
transcriptional activity
189-192
. Our in vitro studies are consistent with γ-secretase-induced 
activation of β-catenin-regulated transcription, as inhibition of β-catenin signaling 
blocked TGF-β3-induced phagocytosis. Our studies utilizing LiCl treatment suggest that 
induction of β-catenin signaling alone may not be sufficient to induce phagocytosis in 
mammary epithelial cells; however, LiCl functions through inhibition of GSK-3β which 
has a diverse array of proposed substrates in addition to β-catenin
193
, and the effect of 
these other targets on inhibiting phagocytosis cannot be discounted. To directly test the 
role of β-catenin in phagocytosis, genetic approaches should be considered, as described 
below. Other possible mediators of phagocytosis downstream of TGF-β3 signaling 
include relocalization of phagocytic receptors to the apical surface and cytoskeletal 
reorganization
194-196
. Furthermore, in addition to regulation of the β-catenin pathway, E-
cadherin also influences the PI3K/Akt, Rho GTPase, and NF-kB pathways, all of which 
have been shown to have a role in phagocytosis
197-200
. 
 Here, pharmacologic approaches were used to discern the roles of γ-secretase and 
β-catenin activity in the induction of a phagocytic phenotype, ultimately revealing a 
working model in which TGF-β3 induces phagocytosis through γ-secretase-mediated 
cleavage of E-cadherin and increased β-catenin activity. To test this model more directly, 
genetic approaches may be used which target each of the components of this proposed 
pathway. In vivo models are not readily available to address this question as there are 
defects in mammary epithelial cell apoptotsis in the absence of TGF-β signaling and the 
intracellular domain of E-cadherin acts as a dominant negative to disrupt cell junctions, 
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thus preventing successful lactation
37, 166, 201
. Therefore, in vitro models are more 
appropriate as a first-step toward using genetic approaches to test this proposed pathway, 
though the effect of these alterations on monolayer formation must be taken into account 
when considering this approach. E-cadherin cleavage by γ-secretase requires binding of 
presenilin 1 to residues 604-615 of the mature processed E-cadherin
202, 203
. While mutants 
lacking this region of E-cadherin cannot be processed by γ-secretase, loss of these 
residues also prevents proper formation of adherens, precluding the use of such a mutant 
in the model described here
203, 204
. Likewise, expression of the cytoplasmic domain of E-
cadherin functions in a dominant negative manner to disrupt the normal structure of both 
adherens and tight junctions, indicating that this approach is also not able to be used to 
investigate the potential role of the cytoplasmic E-cadherin fragment generated by γ-
secretase cleavage in phagocytosis
201, 205
. More feasible is targeting the expression of β-
catenin to more specifically determine β-catenin necessity and sufficiency in the 
induction of a phagocytic phenotype. Overexpression of β-catenin in EpH4 cell 
monolayers may be possible through retroviral transduction of constitutively stable β-
catenin, which lacks the phosphorylation sites required for degradation. Alternatively, 
reduced β-catentin signaling may be achieved through transduction with a dominant 
negative β-catenin. 
 Our work raises many intriguing questions regarding the role of phagocytic 
mammary epithelial cells in vivo. The correlation between decreased junctional integrity 
and increased phagocytic capacity indicates that loss of cell junctions may be an 
important step in mammary epithelial cells becoming phagocytic upon the switch from 
lactation to involution; however, cell junctions are tighter during lactation than any other 
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stage, begging the question of whether or not mammary epithelial cells are normally 
phagocytic except for during lactation, or if their phagocytic phenotype is specific to 
postpartum involution. Given that the mammary epithelium undergoes small cycles of 
proliferation and apoptosis in response to ovarian hormone cycling
206
, it is possible that 
mammary epithelial cells also function in efferocytosis to maintain tissue homeostasis in 
the non-pregnant, premenopausal state. However, MR expression by mammary epithelial 
cells in human breast tissue exclusively during early involution suggests that even if 
mammary epithelial cells have a basal phagocytic capacity, they obtain an even more 
unique phagocytic phenotype during postpartum involution. Murine models utilizing up-
the-teat injections of carboxylated latex beads, apoptotic cells, and other targets of 
engulfment will provide further insight into the extent of the phagocytic capacity of the 
mammary epithelium across reproductive stages. MR expression during postpartum 
involution indicates that the phagocytic role of mammary epithelial cells during this time 
extends beyond that of apoptotic cell clearance. A likely role for mammary epithelial 
cells expressing MR during involution is in the clearance of milk constituents, such as 
hydrolases, peroxidases, and glycoproteins, which are known targets of MR-mediated 
engulfment
176
 that are also found in milk. Additionally, the capability of MR to bind 
mannose, fucose, or N-acetylglucosamine, sugars most commonly found on 
microorganisms, indicates that mammary epithelial cells may also have a role in host 
defense during involution. 
 In summary, we have developed an in vitro model to study the induction of 
phagocytosis in mammary epithelial cells. While the work described here focuses 
specifically on TGF-β3-mediated phagocytosis through γ-secretase and β-catenin, this 
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model is broadly applicable to the general study of phagocytosis by mammary epithelial 
cells. Utilizing TGF-β3 treatment, additional mechanisms involved in the acquisition of 
the phagocytic phenotype may be explored, as well as the range of targets that can be 
phagocytosis by the mammary epithelium. Additionally, this model may also be used to 
to investigate the consequences of apoptotic cell clearance by mammary epithelial cells 
on the local immune environment. Induction of local immune suppression by phagocytes 
is a well characterized event associated with the engulfment of apoptotic cells
85-87
. In 
work described in Appendix A of this thesis, the in vitro model described here is utilized 
to begin to explore the effects of apoptotic cell clearance by mammary epithelial cells on 
macrophage phenotype. Given the negative consequences of defective apoptotic cell 
clearance in the mammary gland, including increased macrophage infiltration, 
vascularization, and tissue fibrosis, it is important to further understanding the 













COX-2 EXPRESSION BY MAMMARY EPITHELIAL CELLS AS A POTENTIAL 




One potential chemopreventive and therapeutic target for postpartum breast 
cancer is cyclooxygenase-2 (COX-2)
207
, a key enzyme in the synthesis of homeostatic 
and pro-inflammatory prostanoids
208
. In rodent breast cancer models, COX-2 
overexpression induces mammary tumorigenesis and associates with multiple tumor-
promotional effects including increased angiogenesis, enhanced tumor cell migration and 
invasion, and reduced anti-tumor immunity
62, 209-213
. Conversely, COX-2 inhibition or 
loss in rodent models reduces mammary tumorigenesis and metastasis
210, 214-216
. Clinical 
data are consistent with similar roles for COX-2 in human breast cancer, as COX-2 
overexpression in breast cancer associates with decreased disease-free and overall 
survival
217, 218
. Additionally, regular use of non-steroidal anti-inflammatory drugs 
(NSAIDs), which inhibit the COX family of enzymes, can reduce overall breast cancer 
risk
219, 220
. In pre-clinical models of postpartum breast cancer, COX-2 has been identified 
as one mediator of tumor promotion during involution
61, 62
. Treatment with both COX-2-
specific and general NSAIDs during postpartum involution ameliorates the tumor-
promotional effects of involution, as evidenced by reductions in tumor size, local tumor 
cell invasion, and tumor cell infiltration into the lung
62
. These studies identified 
upregulation of COX-2 in tumors cells that have been exposed to the involution 
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environment as one target of NSAID treatment during involution
62
. In support of similar 
COX-2 upregulation occurring in human breast cancers that have been exposed to 
involution, DCIS lesions from postpartum breast cancer patients have increased COX-2 
expression compared to DCIS in nulliparous women
62
. Importantly, increased COX-2 
expression in the presence of high collagen I is associated with poorer survival in this 
population
62
. In addition to NSAID treatment targeting tumor cells exposed to the 
involution environment, NSAIDs also reduce tumor promotion during involution by 
targeting the normal mammary gland
61
. When mixed with human breast cancer cells, 
mammary extracellular matrix (ECM) isolated from involution rats promotes tumor cell 
growth and metastasis in vivo, as well as invasive organoid formation in 3D cell culture 
when compared to ECM isolated from nulliparous rats
47, 61
. Importantly, systemic 
treatment of rats with NSAIDs specifically during involution inhibits the tumor-
promotional properties of involution ECM
61, 221
. In these studies, tumor cells were never 
exposed to NSAIDs, only to ECM isolated from NSAID-treated animals, indicating that 
COX-2 expression in the normal postpartum involuting mammary gland was the target 
NSAID treatment
61
. Altogether, these preclinical models suggest that targeting COX-2 
expression during involution with NSAIDs may be one chemopreventive and/or 
therapeutic strategy for postpartum breast cancer. 
To begin to translate these preclinical data into human trails, additional 
understanding is needed regarding COX-2 expression in the mammary gland. Given the 
known role for secretion of the COX-2 product PGE2 by phagocytes upon engulfment of 
apoptotic cells
92
, we predict that COX-2 expression by mammary epithelial cells may be 
a target of NSAID treatment during involution. One important step in addressing this 
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hypothesis is to evaluate COX-2 expression in young women‘s breast tissue. Here we 
utilized human and rodent mammary tissues to investigate COX-2 expression in normal 
tissue across the pregnancy-lactation-involution cycle. Additionally, we explored the link 
between COX-2 expression in histologically normal adjacent breast tissue, DCIS, and 
invasive ductal carcinoma (IDC) in young onset breast cancer cases. We find that COX-2 
expression is primarily epithelial and varies greatly between individual women, with 
evidence for modulation by ovarian hormones. In addition, analysis of COX-2 expression 
in matched normal, DCIS, and IDC from the same patient reveals that COX-2 expression 
in the normal epithelium associates with COX-2 expression in DCIS and IDC. Of 
particular relevance to postpartum breast cancer, a trend toward increased COX-2 
expression in DCIS was observed in patients within 0-2 years of a recent pregnancy 
compared to nulliparous patients. Altogether, these data suggest that factors regulating 
COX-2 expression in normal breast epithelium influence COX-2 levels in breast cancer, 
and indicate that further research is warranted into whether women with high COX-2 
expression may preferentially benefit from COX-2 inhibition strategies. 
Materials and Methods 
Human Tissue Acquisition  
Breast specimens from 96 premenopausal women ages 20-45 who underwent 
clinically indicated biopsy (n=10) or surgery (n=86) were obtained under University of 
Colorado Institutional Review Board (COMIRB) approved protocols. Eighty-six 
specimens were obtained through a HIPPA-exempt, consent-exempt retrospective cohort 
study with IRB approval (COMIRB 05-0958) and 10 were obtained through a subsequent  
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prospective full-consent cohort study (COMIRB 09-0583 and 08-0104). Histologically 
normal tissue, DCIS, and IDC were identified by pathologic review. In 11 cases, COX-2 
expression in the normal epithelium adjacent to cancer was compared to expression in a 
separate quadrant of the breast to determine if COX-2 expression in the histologically 
normal epithelium is influenced by location. For reproductive stage and epithelial-stromal 
analyses, 28 cases with clinical reproductive histories were grouped by reproductive 
categories of nulliparous (n=7), pregnant (n=5), postpartum involuting (within 2 months 
of parturition or lactation, n=7), and fully-regressed parous (7-22 years post-parturition, 
n=9). Thirty-seven cases were used for comparison of paired normal adjacent breast 
epithelium, DCIS, and IDC within the same breast. For correlations, 46 cases were used 
for normal and DCIS, and 57 for normal and IDC. To determine COX-2 expression over 
time, an independent cohort of 6 premenopausal cases with serial biopsies 2-3 weeks 
apart were analyzed.  
Animal Husbandry, Reproductive Staging, and Hormone Stimulation 
Animal procedures were approved with ethical consideration by the University of 
Colorado Anschutz Medical Campus Institutional Animal Care and Use Committee. 
Sprague Dawley rats (Harlan Laboratories, Indianapolis, IN) were housed in static caging 
with 12hr light/dark cycles and access to food and water ad libitum. To obtain distinct 
reproductive states, female rats ~70 days of age were bred, and mammary tissue 
harvested from age-matched virgin; pregnant (days 18-20); lactation (days 10-11); 
involution day 2, 4, 6, 8, and 10 (2-10 days post-wean); and fully regressed rats (4 weeks 
post-wean) as described
55
. For estrous cycle studies, serial vaginal smears were  
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performed and mammary glands harvested at proestrus, estrus, and diestrus 1 and 2 
stages as described
222
. Vaginal smear data were confirmed by cervical histology
222
. For 
estradiol treatment, virgin female rats ~65 days of age were injected subcutaneously with 
5 µg 17-β-estradiol (Sigma-Aldrich, St. Louis, MO) in 250 µl sesame oil or sesame oil 
alone daily for 3 days, and sacrificed 3 days post-treatment. For estradiol plus 
progesterone treatment, female rats ~56 days of age were injected subcutaneously with 5 
µg 17-β-estradiol plus 1.5 mg progesterone (Sigma-Aldrich, St. Louis, MO) in 50 µl 
sesame oil or sesame oil alone daily for 7 days, and sacrificed 24-48 hours post-
treatment.  
IHC, Image Acquisition, and Quantification 
Four µm thick formalin-fixed, paraffin-embedded sections were deparaffinized, 
rehydrated, and sequentially subjected to Dako TRS Antigen Retrieval Solution (125
o
C 
under pressure for 5 minutes; Dako, Carpinteria, CA), Dual Endogenous Enzyme Block 
(10 minutes; Dako, Carpinteria, CA), and Protein Block (10 minutes; Dako, Carpinteria, 
CA). Tissue sections were incubated in primary antibody (1 hour, room temperature; 
human: Cayman Chemical 160112; rat: Cayman Chemical 160106; Ann Arbor, MI) 
followed by Envision Plus Rabbit (30 minutes, room temperature; Dako, Carpinteria, 
CA). Immunoreactivity was visualized using 3,3‘-diaminobenzidine (Dako, Carpinteria, 
CA). Primary antibody specificity was confirmed in human by incubating 1:1 with COX-
2 blocking peptide prior to staining (Cayman Chemical, Ann Arbor, MI) (Figure 4-1A), 
and in rodent by staining mammary tissue from a COX-2 knockout mouse, kindly 
provided by Christopher Rivard, University of Colorado AMC (Figure 4-1B).  
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Figure 4-1. Confirmation of human and rodent COX-2 antibody specificity. A) 
Human COX-2 IHC in normal adjacent tissue and tumor using primary antibody alone or 
primary antibody in combination with COX-2 blocking peptide. B) Rodent COX-2 IHC 
using mammary tissue from the COX-2 knockout mouse. C) Western blot for rodent 
COX-2 using C57Bl/6 primary macrophage lysate as a positive control (Ctrl) and 




COX-2 stained slides were acquired using a ScanScope T3 scanner at 0.46 µ per 
pixel. Aperio analysis software and a color deconvolution algorithm (thresholds: 
clear=240, weak positive=225, medium positive=198, strong positive=150) were used to 
quantify staining intensity (Figure 4-2). For all COX-2 analyses, the operator was blinded 
to study design. For COX-2 quantification of histologically normal adjacent breast tissue, 
lobules of representative COX-2 staining and size were quantified. Representative 
lobules were chosen based on pathologic review by a clinical pathologist blinded to study 
design. When possible, 10 representative lobules per case were analyzed; however, in 
cases with limited epithelium due to biopsy method (i.e. surgical vs. needle), or high 
stroma or tumor content, at least 5 lobules per case were analyzed, for a total of 693  
lobules across cases. To quantify epithelial and stromal COX-2, the stroma within each  
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lobule (intralobular stroma) and the stroma between lobules (interlobular stroma) were 
analyzed separately. To determine epithelial-only stain, the intralobular stroma signal was 
subtracted from the whole lobule signal. For alveolar:ductal COX-2 analysis, 5-7 ducts 
and 5 alveoli per duct were analyzed per case. For quantification of COX-2 expression in 
rat mammary glands, 10 representative fields per animal were analyzed (n=4 
animals/reproductive stage). To control for changes in adipose tissue, lumen size, and 
cellular content in the rat mammary gland across reproductive stage, COX-2 stain was 
normalized to the total number of nuclei. 
Immunoblotting 
Pooled rat mammary tissue lysates (n=6 animals/reproductive group) were 
prepared as described
56
. Forty µg of total protein was separated by SDS-PAGE and  
immunoblotting was performed using polyclonal rabbit anti-COX-2 (160106 Cayman 
Chemical, Ann Arbor, MI) and monoclonal anti-actin (Chemicon, Billerica, MA) 
followed by anti-rabbit or -mouse HRP-conjugated secondary antibody (Bio-Rad 
Laboratories, Hercules, CA, and Santa Cruz Biotechnologies, Santa Cruz, CA, 
respectively) with detection using ECL Western Blotting Substrate (Thermo Fisher 
Scientific, Waltham, MA). COX-2 antibody specificity was confirmed using mammary 
tissue from COX-2 knockout mice described above (Figure 4-1C). Densitometry was 
performed using Image J Software
175
. 
Statistical Analyses  
For analysis of COX-2 expression across reproductive stages and following 
estrogen or estrogen plus progesterone treatment, unpaired one-tailed T tests were used to 
test for increased COX-2 expression compared to nulliparous/virgin or vehicle. Two-
67 
tailed T tests were used for comparison of COX-2 low, medium, and high levels in 
normal adjacent, DCIS, and IDC groups, as well as for analyses of COX-2 expression in 
the normal epithelium in relation to DCIS grade, tumor grade, tumor stage, and estrogen 
receptor (ER), progesterone receptor (PR), and HER2 status. Welch‘s correction was 
applied where variance between groups was unequal. For linear regression analyses, 
Gaussian distributions were assumed and the Pearson correlation coefficients were 
calculated. Statistical analyses were performed using GraphPad Prism v.6 software. 
Results 
Wide Range in COX-2 Expression across Premenopausal Human Breast Tissue 
To investigate COX-2 expression in the premenopausal human breast, 
quantitative COX-2 immunohistochemical analyses were performed on breast tissue  
obtained from women 20-45 years of age. First, the effect of tumor proximity on COX-2 
expression in normal adjacent epithelium was assessed, as field effects in adjacent normal 
epithelium are well documented, as reviewed previously
223
. In a subset analysis (n=12), 
proximity to tumor did not significantly affect adjacent normal COX-2 expression, 
indicating that COX-2 expression in normal breast tissue can be assessed in breast cancer 
cases (Figure 4-3). In all cases containing normal epithelium (n=66), the normal breast 
tissue stained positively for COX-2 though the percent positivity of the tissue varied over 
40-fold (1.8-71%, Figure 4-4A). Further, the mammary epithelium was the dominant 
source of COX-2, demonstrating a range of low, moderate, and high expression and 
accounting for ~94% percent of the total signal (Figures 4-4B and C). Based on the 




Figure 4-2. Quantification of COX-2 staining intensity using Aperio Analysis 
Software. Regions of interest were positively annotated on whole slide images, and 
staining intensity analyzed for negative (blue), weak (yellow), medium (orange), and 
strong (red) staining intensity. 
 
 
reproductive state contributes to COX-2 expression in normal breast tissue. Cases with 
clinical reproductive histories (Table 4-1) were separated into nulliparous, pregnant, 
postpartum involution, and fully-regressed parous groups. A marked ~7-fold increase in 
total lobule COX-2 expression was observed in pregnant cases compared to nulliparous 
controls (Figures 4-4D and E). During pregnancy, COX-2 upregulation occurred 
predominantly in the alveoli (Figures 4-4F and G). COX-2 expression in the normal 
breast also increased in postpartum involution cases, but to a lesser extent than during 
pregnancy (Figures 4-4D and E). In fully-regressed breast tissue from parous women, 
expression levels returned to nulliparous baseline levels (Figure 4-4D and E). Further, 
COX-2 expression was independent of patient age or body mass index (BMI) (Figures 4-
5A and B). Based on the known role for COX-2 stromal cells during wound healing and 
inflammation (reviewed by Smith et al.
224
), we investigated COX-2 expression 
specifically within the intralobular (within a lobule) and interlobular (between lobules) 
69 
 
Figure 4-3. COX-2 expression in histologically normal epithelium does not differ 
with proximity to tumor. Percent COX-2
+
 epithelium in breast tissue adjacent to tumor 
(adjacent) and in a quadrant of the breast not containing tumor (distant) (n=11). p=0.16, 
one-tailed paired t-test. 
 
 
stromal compartments. These analyses confirmed that COX-2 induction during 
pregnancy is predominantly epithelial, and also identified a small, but significant increase 
in the intralobular stroma (Figures 4-4H, I; Figure 4-5); similar trends were observed 
during involution (Figure 4-4H, I; Figure 4-5). Quantification of COX-2 in the 
interlobular stroma revealed no significant changes across stages (Figure 4-4J, Figure 4-
5). These data are consistent with coordinated regulation of COX-2 within the epithelium 
and intralobular stroma during pregnancy, but not within the interlobular stroma.  
 








Cases (n) 7 5 7 9 
Avg. Age (years) 35.6 ± 6.5 34.0 ± 7.7 28.9 ± 7.0 40.9 ± 4.1 
Avg. Gravidity 0 1.50 ± 0.7 2.3 ± 0.5 3.3 ± 1.4 


































2 months of parturition or lactation 
†greater than 7 years post-parturition 
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Figure 4-4. Normal breast tissue COX-2 expression is primarily epithelial and 




Figure 4-4. Normal breast tissue COX-2 expression is primarily epithelial and 
regulated by pregnancy and postpartum involution. A) COX-2 expression varies 
greatly by case. B) COX-2 IHC (brown signal) images representative of low, moderate, 
and high expression cases. C) Relative stromal and epithelial contribution to the total 
lobular COX-2 signal. D, E) Representative COX-2 IHC (D) and percentage of lobular 
area positive for COX-2 (E) in breast tissue from nulliparous (nullip), pregnant (preg), 
postpartum involution (inv), and parous cases. F) COX-2 staining in human breast at ~8 
weeks gestation demonstrating upregulation of COX-2 specific to hormone-responsive 
alveolar epithelium. G) Ratio of alveolar to ductal COX-2 stain in the breast across 
reproductive stages demonstrating preferential upregulation of COX-2 in alveoli with 
pregnancy and involution. H-J) Percentage of epithelium (H), intralobular stroma (I), and 
interlobular stroma (J) positive for COX-2. *p<0.05, one-tail unpaired t-test; **p<0.01, 




Figure 4-5. COX-2 IHC expression in normal adjacent breast epithelium is 
independent of age (A) and BMI (B). A) Pearson‘s r=0.039; p=0.76, two-tailed B) 
Pearson‘s r=-0.0067; p=0.96, two-tailed 
 
 
Evidence for Ovarian Hormone Regulation of COX-2 
Having demonstrated COX-2 upregulation during pregnancy in women, the 
Sprague Dawley rat model was utilized to investigate mammary tissue COX-2 expression 
across defined pregnancy, lactation, and postpartum involution time points. COX-2 
expression in the mammary epithelium was low in virgin (nulliparous) rats, increased 
significantly during pregnancy, and was lost during lactation (Figures 4-6A and B). 
Following lactation, epithelial COX-2 gradually increased across mid- to late-involution 
(Inv days 6, 8 and 10), and returned to baseline levels in the fully regressed gland 
(Figures 4-6A-B). These data were verified by immunoblot for all stages except lactation 
(Figure 4-6C). By IHC, COX-2 stain was low in the lactating gland and restricted to 
apical, vesicle-like structures budding off the lactating mammary epithelium (Figure 4-
6A); however, by immunoblot, COX-2 levels were highest during lactation (Figure 4-
6C). Based on these disparate observations, we speculate that COX-2 is localized in the 
membrane of secreted vesicles during lactation and secreted with milk. Thus, the 
discrepancy between the IHC and immunoblot data may be explained by the fact that  
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most milk is lost from the gland during IHC preparation, but remains in the tissue lysate 
utilized for immunoblot. Of note, a putative role for COX-2 in milk or milk production 
has not been reported, warranting additional investigation into this observation.  
 
 
Figure 4-6. COX-2 is upregulated in the rat mammary gland during pregnancy and 
postpartum involution. A) Representative COX-2 IHC (brown signal) in rat mammary 
glands from vir=virgin, preg=pregnancy days 18-20, lac=lactation day 10, inv2-
10=involution day 2-10, parous=4 weeks post-wean; inset=epithelial staining at higher 
magnification. B) Percent COX-2
+ 
area normalized to number of nuclei in rat mammary 
tissue across the reproductive cycle. C) Western blot for COX-2 and actin using pooled 





To explore the role of ovarian hormones in COX-2 regulation, COX-2 expression 
was evaluated by IHC across the rat estrous cycle. COX-2 expression in the mammary 
epithelium increased modestly during estrus and diestrus 1 stages of the estrous cycle 
(Figure 4-7A), consistent with estrogen and progesterone regulation. Of potential 
relevance, the range of COX-2 expression levels in the nulliparous rat across estrous 
stages is similar to that observed in our premenopausal nulliparous and fully-regressed 
parous human cohorts (Figure 4-4E). In the rat, direct evidence for ovarian hormone 
regulation was demonstrated by COX-2 upregulation in the mammary epithelium 
following estradiol and estradiol plus progesterone treatment designed to mimic the 
biologic effects of pregnancy (Figure 4-7B). The magnitude of COX-2 upregulation 
following treatment is comparable to that observed in breast tissue of women during 
pregnancy (Figure 4-4D and E). 
Coordinated COX-2 Expression in Normal Epithelium, DCIS, and Breast Cancer 
Given the wide range of COX-2 expression in the normal premenopausal human 
breast (Figure 4-4A and B), and the reported poor prognosis associated with COX-2 
upregulation in breast cancer
217, 218
, we investigated the relationships between COX-2 
expression in normal adjacent breast tissue, DCIS, and IDC. A quantitative assessment of 
COX-2 expression was performed using matched normal adjacent and DCIS lesions 
within a single tissue section from the same case (n=46), as well as matched normal 
adjacent and IDC, also from a single tissue section (n=57), obtained from the cohort 
described in Table 4-2. COX-2 expression in the normal adjacent epithelium strongly 
correlated with DCIS COX-2 expression (Figure 4-8A), and moderately correlated with  
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Figure 4-7. Evidence for ovarian hormone regulation of COX-2 in rat mammary 
epithelium. A) Representative IHC (left, brown signal) and quantification (right) of 
COX-2 expression in rat mammary tissue across the estrous cycle; p=0.38, One-way 
ANOVA. B) COX-2 IHC (top) and quantification (bottom) in rat mammary tissue 
following estradiol (left) or estradiol+progesterone (right) treatment. veh=vehicle, 
E=estradiol, E+P=estradiol plus progesterone; *p<0.05, one-tailed unpaired t-test; 
**p<0.01, one-tailed unpaired t-test 
 
 
COX-2 expression in IDC (Figure 4-8B). Thirty-seven cases containing normal, DCIS, 
and IDC on the same tissue section were then stratified into categories of low, moderate, 
and high normal epithelium COX-2 expression. We found that cases with low adjacent 
normal COX-2 expression also had low expressing DCIS and IDC (Figure 4-8C). 
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Similarly, cases with moderate and high adjacent normal COX-2 expression had 
moderate and high DCIS and IDC expression, respectively (Figure 4-8C). When 
comparing normal adjacent, DCIS, and IDC within the same case, COX-2 expression was 
highest in the adjacent normal tissue, decreased in the matched DCIS, and further 
decreased in the matched IDC lesion (Figure 4-8C). Importantly, COX-2 expression in 
the normal adjacent epithelium was not associated with DCIS or IDC grade, stage, or ER, 
PR, or HER2/neu status (Figures 4-8D-G), indicating that, in our cohort, COX-2 
expression in the normal epithelium is not driven by the disease state. This observation is 
further supported by evidence that COX-2 expression in the normal epithelium also did 
not differ significantly with proximity to the tumor (Figure 4-3). Altogether, these data 
suggest that women can be segregated into groups of low, moderate, and high COX-2 
expression based on the expression levels in their normal breast epithelium, and that 
factors underlying COX-2 expression in the normal epithelium may influence COX-2 
expression in DCIS and IDC.  
In order for COX-2 expression in the normal breast epithelium to be considered as 
a potential risk factor for breast cancer in young women, the distinct baseline levels of 
low, moderate, and high COX-2 expression in the normal epithelium would need to 
remain relatively stable over time. However, an important potential caveat raised by our 
data demonstrating ovarian hormone modulation is whether a single breast biopsy can 
predict overall COX-2 expression in young, premenopausal women. To begin to address 
this question, COX-2 expression was analyzed in a distinct cohort of premenopausal 
cases (n=6) who received serial breast biopsies 2-3 weeks apart, allowing for analysis 
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Table 4-2. Clinical characteristics of cases used for normal adjacent, DCIS, IDC and 
serial biopsy analyses. 
 
 Normal Adjacent, 




Cases (n) 83 6 
Avg. Age (years) 37.5±5.6 35.8±10.5 
Avg. BMI  25.4±6.1 24.8±1.5 
Avg. Gravidity 2.2±1.6 1.8±1.3 
















Histological Subtype  
Ductal 
Lobular 











































































Tumor Size  
< 2 cm 
≥ 2 cm 





















Lymph Node Involvement 
Present 
Absent 











Figure 4-8. COX-2 expression in normal breast epithelium associates with COX-2 
expression in matched DCIS and IDC. A) Correlation between COX-2 expression in 
matched adjacent normal and DCIS. B) Correlation between COX-2 expression in 
matched adjacent normal and IDC. C) Stratification of cases based on low, moderate, and 
high COX-2 expression in the normal adjacent epithelium. D-G) COX-2 expression in 
normal epithelium is not associated with DCIS grade (D), tumor grade (E), tumor stage 
(F), and biologic subtype (G). H) COX-2 expression in serial biopsies separated in time 
by 2-3 weeks. *p<0.05, two-tailed unpaired t-test; **p<0.01, two-tailed unpaired t-test; 
***p<0.001, two-tailed unpaired t-test; ****p<0.0001, two-tailed unpaired t-test 
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of COX-2 expression in a single case at two different time points during physiologic 
menstrual cycling. The patient characteristics of this smaller cohort were reflective of the 
larger cohort used for the normal adjacent, DCIS, and IDC analysis in terms of age, BMI, 
parity, histological and tumor subtype, and stage (Table 4-2). In 5 out of 6 cases, the 
relative COX-2 expression (i.e, low, moderate, high category) remained within the same 
category between biopsies, while one case moved from the high to moderate category 
(Figure 4-8H). While this is a small cohort, these data suggest COX-2 expression data 
obtained from a single breast biopsy may prove to be a valid indicator of individual 
baseline COX-2 expression levels in young women. 
COX-2 Expression in Postpartum Breast Cancer Patients 
 To determine if postpartum breast cancer patients have increased COX-2 
expression in the normal mammary epithelium or tumors, patients within 2 years of a 
recent pregnancy were compared to age-matched, nulliparous women. Compared to 
nulliparous controls, a trend toward increased COX-2 expression was observed in the 
normal breast epithelium and DCIS of women within 2 years of a recent pregnancy 
(Figures 4-9A and B). This trend did not exist for IDC, as COX-2 expression in IDC was 
equivalent in nulliparous and postpartum women (Figure 4-9C). These data are consistent 
with correlations shown above (Figures 4-8A and B) demonstrating a stronger correlation 
between COX-2 expression in normal and DCIS than normal and IDC. 
Discussion 
A young women‘s breast tissue cohort and rat models were used to investigate 
COX-2 expression in histologically normal mammary epithelium and the relationship 
between normal adjacent and breast cancer COX-2 expression. This is the first study to  
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Figure 4-9. COX-2 expression in normal, DCIS, and IDC in postpartum, pre-
menopausal women. A-C) COX-2 expression in normal (A), DCIS (B), and IDC (C) in 
nulliparous women and women within 2 years of a recent pregnancy. 
 
 
address COX-2 expression exclusively in breast tissue of premenopausal women, ages 45 
years and younger, and to utilize computer-based analysis software to quantify COX-2 
expression separately in the mammary epithelium and stroma. We found the epithelium 
to be the dominant source of COX-2 in normal adjacent breast tissue, with a ~40-fold 
range in expression across cases. Cumulatively, our studies implicate differential baseline 
levels of COX-2 expression between women, which can be influenced by ovarian 
hormones. Moreover, COX-2 expression in the normal breast epithelium paralleled COX-
2 expression in DCIS and IDC. These data are consistent with results obtained from 
predominantly post-menopausal cohorts in which COX-2 expression was also observed 
in the breast epithelium and correlated with DCIS and invasive cancer expression
217, 225-
227
. It has previously been proposed that field effects emanating from pre-malignant tissue 
or overt cancer are responsible for high COX-2 expression in normal adjacent 
epithelium
226, 228
; however, our data demonstrate COX-2 expression in the normal 
epithelium is independent of known clinical prognostic features and support an 
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alternative hypothesis where physiologic regulators of COX-2 expression in the normal 
breast epithelium influence DCIS and IDC COX-2 expression levels. 
The observation that baseline COX-2 levels in the breast vary dramatically 
between young women raises two provocative but unanswered questions: whether high 
baseline COX-2 expression can predict risk of young onset breast cancer, and whether 
women with high baseline COX-2 expression would preferentially benefit from COX-2 
inhibition strategies (modeled in Figure 4-10). Consistent with a promotional role for 
COX-2 in breast cancer risk, increased COX-2 expression in the breast epithelium is 
associated with pre-malignancy and induces mammary tumor formation in mice
213, 228
. 
Furthermore, in women, high COX-2 expression in atypia is associated with increased 
breast cancer risk
229
. Importantly, a requisite for normal breast COX-2 expression to be 
predictive for breast cancer risk is that COX-2 expression remains relatively constant 
across time. Our data demonstrating ovarian hormone modulation of COX-2 in normal 
breast epithelium would be expected to reduce the predictive value of COX-2 expression 
in young women. To address this concern, we performed a serial biopsy analysis in a 
small cohort of individual, premenopausal women that revealed relative stability in COX-
2 expression levels over time. One interpretation of these data is that menstrual cycle-
driven fluctuations in COX-2 expression occur within the context of a relatively stable 
baseline level of COX-2 expression. A larger sample size is necessary to address this key 
point, as well as to address potential mechanisms determining baseline COX-2 expression 
levels. Clinical relevance lies in the fact that 70-80% of the approximately 1 million 
clinical breast biopsies per year in the United States alone reveal a benign diagnosis
230, 
231
. For the vast majority of these women, molecular strategies to identify high risk 
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populations are absent, leaving populations of high-risk women unidentified. Data from 
our cohort suggest that as many as 30% of young women have high baseline COX-2 
expression. The validation of our results demonstrating stable categories of low, medium, 
and high baseline COX-2 expression would argue for future studies to investigate the 
relationship between normal epithelial COX-2 expression and breast cancer risk.  
 
 
Figure 4-10. Model of the relationships between COX-2 expression in the normal 
epithelium, DCIS, and invasive breast cancer in premenopausal women. Baseline 
COX-2 expression in the normal breast epithelium varies across individual 
premenopausal women and can be modified by estrogen (E) and progesterone (P) 
exposure. Young women with increased COX-2 expression in the normal epithelium are 
predicted to have increased risk for breast cancers with a poor prognosis, and may be 
candidates for chemoprevention strategies targeting COX-2. 
 
 
 The association between COX-2 staining in the normal adjacent epithelium and 
breast cancer implies that if young women with high baseline COX-2 levels develop 
breast cancer, their tumors will also express high levels of COX-2 (Figure 4-10). This is 
of prognostic significance, as COX-2 expression is an independent predictor of decreased 
disease-free and overall survival
217, 218
. Thus, understanding mammary COX-2 regulation 
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and expression in young women may aid in identifying novel treatments for patients 
whose tumors express increased COX-2. This concept is also supported by others who 
propose that understanding COX-2 expression in the normal breast epithelium is 
necessary to gain insight into COX-2 expression in cancer
217, 225, 226
. Our data showing 
regulation of COX-2 by estrogen and progesterone raise intriguing questions such as 
whether increased baseline COX-2 expression in young women‘s breast tissue is 
associated with early menarche, contraceptive use, or pregnancy history. Somewhat 
surprisingly, a relationship between BMI and COX-2 expression in the normal adjacent 
breast epithelium was not observed in our cohort, though additional work is warranted to 
address this relationship further. Additionally, given the upregulation of COX-2 observed 
during postpartum involution and the trend toward increased COX-2 expression in the 
normal epithelium and DCIS of women within 2 years of a recent pregnancy, women 
undergoing postpartum breast involution may present a population where understanding 
physiologic regulation of COX-2 expression may be particularly beneficial. T 
hough only a trend in increased COX-2 expression in normal breast epithelium and DCIS 
was detected in postpartum women in this dataset, these data are consistent with work 
published by Lyons and O‘Brien et al. that utilizes a larger dataset to demonstrate a 




Data from colorectal cancer indicate that identifying patients whose tumors have 
high COX-2 expression may be a key step in achieving a survival benefit with NSAID 
treatment
232
; however, data from the Nurses‘ Health Study indicate the survival benefit of 




. However, it remains unexplored whether young premenopausal breast cancer 
patients present a unique population where baseline COX-2 levels do impact outcomes. 
Given the high level of physiologic tissue remodeling that occurs in the breasts of young 
women
69
 and the links between COX-2, tissue remodeling, and breast cancer, further 
investigations into the potential benefits of NSAID treatment in young women‘s breast 
cancer are warranted.  
In summary, we demonstrate high variability in COX-2 expression in normal 
breast epithelium between young women and provide evidence for hormone regulation. 
Furthermore, we provide evidence that the mediators of physiologic COX-2 expression 
also influence expression in DCIS and breast cancer. These data provide impetus to 
further determine how COX-2 expression levels are regulated in the normal human 
breast, as baseline COX-2 expression levels may inform breast cancer risk assessment, 
chemopreventive efficacy of NSAIDs, and utility of COX-2 targeted therapies in young, 





Summary of Key Findings 
 The process of postpartum mammary gland involution is tumor-promotional and 
hypothesized to be a primary driver behind the poor prognosis of postpartum breast 
cancer
28, 47, 57, 61, 62
. Understanding the normal biology of postpartum involution is 
anticipated to reveal targets for postpartum breast cancer prevention and treatment. While 
multiple attributes of involution are predicted to contribute to tumor promotion
3, 28, 47, 55, 
57, 61, 62, 129
, the work in this thesis is directed toward understanding the role of efferocytic 
mammary epithelial cells in contributing to a tumor promotional immune environment in 
the involuting mammary gland.  
As a first step toward investigating the immunomodulatory properties of 
efferocytic mammary epithelial cells, a novel model was developed to study phagocytosis 
by mammary epithelial cells in vitro. A distinguishing feature of this model is that 
mammary epithelial cells are allowed to form a mature, polarized monolayer with 
impermeable tight cell junctions prior to the induction of a phagocytic phenotype. 
Monolayer formation and establishment of closed tight junctions in this model mimic the 
unique impermeability of the epithelium which is observed in the mammary gland only 
during lactation
139, 144
. The establishment of this model system is an important 
contribution to the study of phagocytic mammary epithelial cells on a number of fronts. 
One application of this model is that it can be used to explore the mechanisms involved in 
the acquisition of a phagocytic phenotype by mammary epithelial cells. In the work 
described here, TGF-β3 treatment resulted in disrupted tight and adherens junctions 
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compared to vehicle, and led to increased phagocytosis through γ-secretase and β-catenin. 
The extent of junction disruption following TGF-β3 treatment correlated to phagocytic 
capacity, implicating cell junction changes in mammary epithelial cells obtaining a 
phagocytic phenotype. Consistent with a role for changes in cell junctions contributing to 
phagocytosis by mammary epithelial cells in vivo, a shift in E-cadherin localization away 
from lateral cell junctions to become apical and cytoplasmic was observed in involuting 
rat and human mammary glands. Furthermore, E-cadherin relocalization associated with 
cleavage of the protein in rat mammary tissue. Consistent with a role for γ-secretase- and 
β-catenin-mediated induction of phagocytosis in mammary epithelial cells in vivo, 
increased γ-secretase activity was observed upon the switch from lactation to involution, 
and E-cadherin cleavage preceded an increase in translocation of β-catenin from the 
lateral cell membranes to the nucleus. 
A second application of this in vitro system is that it can be used as a means to 
investigate growth factors, chemokines, and cytokines secreted by efferocytic mammary 
epithelial cells, which may contribute to a tumor-promotional environment in the 
postpartum involuting mammary gland. Using the model in this fashion, VEGF was 
identified as a growth factor secreted by efferocytic mammary epithelial cells, which may 
contribute to a tumor promotion in the involuting gland through the stimulation of 
angiogenesis and or lymphangiogenesis, as well as potentially having direct effects on 
tumor cell growth
234-239
. Additionally, efferocytic mammary epithelial cells were 
demonstrated to promote macrophages with characteristics of both classical and 
alternative activation. These include decreased expression of mannose receptor, AIF-1, 
and CD86, as well as a slight increase in Arg-1. Downregulation of CD86 is of particular 
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interest, as CD86 is a co-stimulatory molecule that promotes T cell activation. If 
efferocytic mammary epithelial cells promote downregulation of CD86 in macrophages, 
this may result in impaired activation of T cell responses against cancer cells, and allow 
the cancer to evade immune surveillance during postpartum involution. 
In addition to developing and utilizing an in vitro model of phagocytic mammary 
epithelial cells to characterize phagocytosis induction by TGF-β3 and the effects of 
efferocytosis on cytokine secretion and macrophage phenotype, my thesis investigates 
COX-2 expression by mammary epithelial cells as a potential target for postpartum breast 
cancer prevention and treatment. Using rodent models targeting the postpartum 
involution window with NSAIDs and celecoxib, others in the Schedin lab identified 
COX-2 as one mediator of tumor promotion during postpartum involution
61, 62
. To begin 
to translate these data into human trails, additional understanding is needed regarding 
COX-2 expression in the mammary gland. Through quantitative immunohistochemical 
techniques, I utilized a premenopausal cohort to identify the mammary epithelial cells as 
the primary cell type expressing COX-2 in the breast. COX-2 expression in the breast 
varied approximately 40-fold across women and was greatly upregulated during 
pregnancy, with a second, smaller peak during postpartum involution. The range in COX-
2 expression observed across this cohort has important implications for cancer, as COX-2 
expression in the normal epithelium correlated with COX-2 expression in DCIS and 
invasive breast cancer. Furthermore, COX-2 expression in the normal epithelium was not 
upregulated in association with cancer, indicating that COX-2 expression in the normal 
epithelium is likely not driven by the cancer. Instead, these data suggest that the factors 
regulating physiologic COX-2 expression in breast normal tissue may drive COX-2 
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expression levels in DCIS and invasive cancer. This is of particular significance given the 
poor prognosis associated with increased COX-2 in breast cancer
217, 218
. These data 
indicate that women with high COX-2 expression in the normal epithelium may be at 
greater risk for developing breast cancer with high COX-2 expression. Additionally, 
these women may be at a particularly increased risk of developing poor prognosis breast 
cancers during the postpartum period, given that COX-2 has been identified as a mediator 
of postpartum breast cancer promotion. 
Future Perspectives and New Questions 
Through microarray and immunohistochemical analyses, immune signaling 
pathways and immune cells have been identified as a major components of postpartum 
involution
54, 55, 59
. Work in the Schedin lab has been directed toward understanding the 
immune milieu in the involuting gland as a potential target for postpartum breast cancer 
prevention and treatment. The work described in this thesis indicate that during 
involution, mammary epithelial cells share multiple attributes with immune cells, such as 
phagocytic capacity, VEGF secretion, and COX-2 expression, and may play an important 
part in the immune signature of involution. Work from others also support an immune-
regulatory role for mammary epithelial cells in the postpartum involuting mammary 
gland. Deletion of the key mediator of inflammation, Stat3, specifically in the mammary 
epithelium, leads to decreased expression of acute phase response and wound-healing 
associated genes, reduced macrophage and mast cell infiltration, and a skewing of the 
macrophage phenotype away from alternative activation toward classical activation
240
. 
Altogether, these data indicate that the immune phenotype of mammary epithelial cells 
should be considered when targeting the immune milieu of involution for postpartum 
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breast cancer prevention and treatment. Given the potential overlap that immune cells and 
mammary epithelial cells may have in effecting the immune milieu of the involuting 
gland, interventions targeting ―effectors‖ of these pathways during involution, such as 
cytokine or MMP secretion, may be more effective than trying to target the immune cells 
themselves, as this strategy will target the immune regulatory properties of both immune 
and mammary epithelial cells. Additionally, the fact that efferocytosis in the mammary 
gland is predominantly the function of epithelial cells and not infiltrating macrophages 
indicates that mammary epithelial cells may have unique immune properties during 
involution that are not shared by immune cells during this time, and that immune 
modulation by the mammary epithelial cells themselves should be further investigated for 
the identification of targets for postpartum breast cancer. 
My data identify a role for changes in cell junctions in the acquisition of a 
phagocytic ability by mammary epithelial cells. Interestingly, E-cadherin has been shown 
to modulate the phenotype of dendritic cells and macrophages leading to the question of 
whether or not changes in E-cadherin can directly regulate cytokine production and 
immune function of mammary epithelial cells. In dendritic cells, physical disruption of 
cell clusters leads to E-cadherin dependent dendritic cell maturation through activation of 
the β-catenin signaling pathway
197
. In these experiments, disruption of E-cadherin-
mediated adhesion resulted in dendritic cell maturation without stimulation of dendritic 
cell cytokine production
197
. However, dendritic cells matured in this fashion induced IL-
10-producing T cells in vitro and immune tolerance in vivo
197
. If E-cadherin disruption in 
mammary epithelial cells induces a similar immune phenotype, this would have 
important implications in postpartum breast cancer as immune tolerance during 
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involution is anticipated to allowed cancer cells to evade the immune system. These data 
suggest it may be worthwhile to investigate the question of whether adherens junction 
changes in the promotion of immune-cell like attributes of the mammary epithelial cells 
extends beyond the induction of phagocytic ability to also include the regulation of 
cytokine production and T cell activation. 
In the course of my thesis studies, I found that γ-secretase activation, E-cadherin 
cleavage, β-catenin nuclear localization, and COX-2 expression were induced in the 
mammary epithelium during involution in vivo. Another question raised by this work is 
what happens when these same programs are activated in tumor cells present in the 
involuting gland? The same signals inducing γ-secretase activity, E-cadherin proteolysis, 
β-catenin nuclear localization and COX-2 expression in the mammary epithelium during 
involuting are predicted to activate the same events in tumor cells, which may contribute 
to pathogenesis of postpartum breast cancer. While the work described here focused 
solely on the intracellular cleavage of E-cadherin by γ-secretase, intracellular cleavage is 
often associated with and follows ADAM10, MMP, or elastase cleavage of the 
extracellular domain of E-cadherin required for lateral cell to cell adhesion
241-243
. 
Extracellular E-cadherin cleavage results in increased motility and invasion of breast 
cancer cells, firstly by decreasing cell-cell adhesion and secondly, by releasing soluble E-
cadherin fragments that are bioactive and stimulate upregulation of MMPs
244
. γ-secretase 
also has roles in breast cancer independent of E-cadherin cleavage by promoting breast 
cancer stem cell renewal through activation of the Notch pathway. Currently, the 
effectiveness of γ-secretase inhibitors in breast cancer is being explored clinically and 




increased β-catenin and COX-2 expression in breast cancer are each independently 
associated with poor outcomes. Preclinical models and outcomes data demonstrate a role 
for COX-2 expression by tumor cells in postpartum breast cancer
62
, consistent with 
programs turning on COX-2 in the normal breast epithelium during involution leading to 
increased COX-2 expression in tumors. While proteolytic processing of E-cadherin, 
Notch signaling, and β-catenin activation have not yet been addressed in postpartum 
breast cancer, future work should be directed toward investigating the potential role of 
each of these events in breast cancers that arise in the postpartum period. 
 Our studies have identified epithelial cell-based immune modulation as a potential 
novel mechanism of targeting breast cancer in the postpartum setting. Importantly, cancer 
therapies are being currently explored in pre-clinical models that target immune 
suppression associated with apoptotic cell clearance as a means of enhancing anti-tumor 
immune responses
101, 104, 247-249
. One main way this is being done is through blocking the 
ability of phagocytic cells to recognize phosphatidylserine exposed on the surface of 
apoptotic cells. Interference of phosphatidylserine recognition leads to an enhanced 
ability of the immune system to eliminate tumor cells and tumor-associated vasculature, 
indicating that blocking phosphatidylserine exposure on apoptotic cells reduces the 
immune-suppressive effects of apoptotic cell clearance
101, 247
. Though the massive 
amount of apoptotic cell clearance in the mammary gland during involution is likely 
associated with the promotion of local immune suppression, which may allow tumors 
cells to avoid detection of the immune system, one must consider the question of what 
would be the best way to target this event for postpartum breast cancer prevention and/or 
treatment. A necessary consideration in identifying interventions targeting the postpartum 
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involution window is that postpartum involution must be allowed to persist unabated and 
without negative consequences. This is true for several reasons, including the fact that 
persistent lactation would likely be unacceptable to non-nursing women, and also because 
inhibited and delayed involution is associated with epithelial hyperplasia and 
desmoplastic stroma
83, 98, 130
. Given these requirements, interventions designed to 
interfere with phosphatidylserine recognition by phagocytes are likely not a viable option. 
Blocking phosphatidylerine on apoptotic cells results in decreased clearance of apoptotic 
cells by professional phagocytes, as well as mammary epithelial cells
79, 97
. During 
involution, deficiencies in apoptotic cell clearance are associated with disruptions in 
tissue homeostasis, which have negative consequences on the subsequent function of the 
mammary gland
83, 98, 130
. Additionally, while blocking phosphatidylserine-dependent 
immune suppression associated with both apoptotic and live tumor cells is advantageous 
for cancer therapy, a loss of immune suppression in the context of physiological apoptotic 
cell clearance can result in autoimmunity
250, 251
, which would be undesirable during 
involution. A better strategy for interventions directed toward the postpartum involution 
window is to identify downstream mediators of tumor promotion that result from 
apoptotic cell clearance, such as VEGF, and focus on targeting these in such a way that 
limits the tumor-promotional properties of the involuting gland without stimulating an 
immune response. 
Significance 
 In the United States, breast cancer is the leading cancer diagnosis in women 
between in the ages of 20 and 45, with an estimated 13% of all breast cancers diagnosed 
in women age 45 and younger
9, 252, 253
. Furthermore, breast cancer is the most common 
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cancer diagnosed in association with pregnancy
254
. Breast cancer diagnosed in the 
postpartum period within five years of a pregnancy has significantly increased metastasis 
and poorer survival rates when compared to age-, tumor stage-, and biologic subtype-
matched nulliparous patients
24
. Over a five-year period, it is estimated that approximately 
34,000 cases of breast cancer will be diagnosed within five years postpartum, and, 
therefore have a recent pregnancy as a negative prognostic factor
24
. Further, increasing 
maternal age is associated with increased risk for and poorer outcomes of breast cancers 
diagnosed in the postpartum period
3
. In 2008, for the first time in recorded history, the 
number of births to women ages 35 and older in the United States exceeded the number 
of births to teens, demonstrating the shift toward delayed childbearing
255
. More recent 
data looking at births in England in 2012 indicate this trend is continuing with greater 
than twice as many babies being born to women between the ages of 25 and 34 compared 
to women under the age of 25
256
. As the trend toward delayed childbearing continues, the 
number of postpartum breast cancer diagnoses is anticipated to rise. Of significance, 
average age at first birth in the US is still lower than any other developed country
257, 258
, 
making breast cancer diagnosis in the postpartum period an emerging, worldwide 
concern.  
 In rodent models, postpartum mammary gland involution has been identified as a 
tumor-promotional period following lactation that may account for the increased rates of 
metastasis and poorer survival observed in postpartum breast cancer patients
47, 61, 62
. One 
chemopreventive and therapeutic strategy for postpartum breast cancer is to target the 
tumor-promotional attributes of postpartum involution
3, 61, 62, 69, 129
. Here, a novel in vitro 
model was developed which may be utilized to identify potential targets for postpartum 
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breast cancer prevention and treatment. Additionally, the IHC analysis of COX-2 
expression in the mammary gland described here, coupled with animal models from 
others in the Schedin lab demonstrating reduced tumor promotion during involution in 
the presence of NSAIDs
61, 62
, identify physiologic COX-2 expression by the mammary 
epithelium as a potential therapeutic target during involution. Furthermore, our data 
identify populations of women with high COX-2 expression in the normal epithelium 
who, we predict, may be at greater risk for developing future breast cancer during the 
postpartum period. Altogether, the work in this thesis provides insight into COX-2 
expression by mammary epithelial cells as a target for postpartum breast cancer 
prevention and therapy, and through development of the in vitro model, provides a means 
to investigate additional targets. Further understanding immune modulation by mammary 
epithelial cells in the postpartum involuting mammary gland is anticipated to identify 
specific preventive and therapeutic targets for women at risk for, and diagnosed with, 
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EFFECTS OF PHAGOCYTIC MAMMARY EPITHELIAL CELLS ON 
MACROPHAGE PHENOTYPE 
Introduction 
 As mentioned briefly in Chapter II, phagocytes functioning in apoptotic cell 
clearance share many attributes with tumor-associated macrophages. In response to 
apoptotic cells, phagocytes upregulate the production of pro-growth and -angiogenic 
factors, such as hepatocyte growth factor (HGF) and vascular endothelial growth factor 
(VEGF)
259, 260
. Importantly, both HGF and VEGF are prognostic indicators in breast 
cancer, with increased expression of HGF and VEGF associated with decreased disease-
free and overall survival
261, 262
. Additionally, clearance of apoptotic cells is associated 
with immunosuppression and the development of immune-tolerance, both of which are 
attributes of tumor-associated macrophages and associated with cancer promotion
263, 264
. 
Immune suppression following apoptotic cell recognition is mediated in part through 
phosphatidylserine-dependent secretion of IL-10, TGF-β and PGE2 by the engulfing 
efferocytes
92
. Furthermore, cell-mediated contact between the apoptotic cell and the 
phagocyte, independent of soluble factors, has also been identified as a means of 
promoting immune suppression in the context of apoptotic cell engulfment
265-267
. In 
support of apoptotic cell exposure leading to the induction of tumor-promotional 
phagocytes, macrophages exposed to apoptotic tumor cells or phosphatidylserine -
exposing microvesicles lose cytotoxicity, enhance tumor growth by 40%, and promote 
metastasis
268, 269
. Importantly, cancers cells have usurped some of the mechanisms of 
immune suppression associated with recognition of apoptotic cells by phagocytes, as a 
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means to evade the immune system. Phosphatidylserine exposure by non-apoptotic 
cancer cells has been reported, and phosphatidylserine exposure has been identified as a 
marker of tumor cells and metastases
249, 270
. Additionally, in mouse models of solid 
tumors, phosphatidylserine is exposed on morphologically intact, non-apoptotic tumor 
vasculature of solid tumors, while phosphatidylserine exposure by vasculature in normal 
tissue is undetectable
271
. This suggests that both upregulation of phosphatidylserine on 
tumor cells and tumor- associated vasculature may be one way by which tumor cells 
suppress the local immune environment and further, may promote macrophages that 
stimulate tumor growth and metastases directly. Furthermore, blocking 
phosphatidylserine exposure represents a potential therapeutic strategy to re-educate the 
immune system against tumors. 
 To date, studies targeting phosphatidylserine exposure in cancer therapy have 
provided further support for phagocyte recognition of phosphatidylserine on apoptotic 
and cancer cells as having an important role in tumor promotion
101, 247
. Injection of 
apoptotic cancer cells has been explored as a method of stimulating an immune response 
against live cancer cells; however, full immunogenic potential of apoptotic cells may not 
be realized without blockade of phosphatidylserine exposure. In a mouse model of 
lymphoma, apoptotic cell injection alone was only weakly immunogenic, but when 
combined with annexin 5, a molecule that blocks phosphatidylserine exposure, the anti-
tumor immune response was greatly enhanced and resulted in tumor regression and 
protection against the development of future tumors
247
. These data indicate that 
phosphatidylserine -dependent immune suppression associated with apoptotic cell 
clearance may be targeted therapeutically to enhance the immune response against 
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cancer. Blocking phosphatidylserine exposure may be particularly effective in 
combination with current therapies designed to induce apoptosis in tumor cells. In a pre-
clinical model of glioblastoma, combination therapy with irradiation and bavituximab, a 
monoclonal antibody against phosphatidylserine, resulted in increased destruction of 
tumor cells and associated vasculature, and doubled the median survival time when 
compared to treatment with irradiation alone
101
. Additionally, 13% of animals that 
received combination treatment remained disease-free and had lasting immunity against 
the development of future tumors
101
. Altogether, these data are consistent with a role for 
phosphatidylserine exposure on apoptotic cells and tumor cells in inducing immune 
tolerance, and indicate that phosphatidylserine exposure on dying cells may be exploited 
as a means of cancer therapy. 
 Given that the local immune environment in areas of apoptotic cell clearance 
shares many similarities with tumor-promotional microenvironments, it is of interest to 
further understand the immune modulatory properties of efferocytic mammary epithelial 
cells in the postpartum involuting mammary gland. In vitro, mammary epithelial cells 
secrete TGF-β and promote immune suppression in response to apoptotic cells, 
suggesting efferocytic mammary epithelial cells may have a role in promotion of cancer 
cells in the postpartum mammary gland
97
. Consistent with a role for efferocytic 
mammary epithelial cells driving a tumor-promotional immune environment in vivo, 
mammary tissue defective in apoptotic cell clearance by mammary epithelial cells has 
reduced levels of TGF-β1
98
. Additionally, during involution, mammary epithelial cells 
express cyclooxygenase-2, a key enzyme in the synthesis of PGE2, which promotes 




. Here, we utilize an in vitro model to investigate cytokine secretion and 
macrophage activation by mammary epithelial cells that have engulfed apoptotic cells. 
By characterizing the immune modulatory properties of efferocytic mammary epithelial 
cells, we anticipate the identification of new targets for the prevention and treatment of 
postpartum breast cancer.  
Materials and Methods 
Generation of Apoptotic Cells 
 EpH4 cells at 95% confluency were harvested with 0.25% trypsin-EDTA, and re-
seeded 1:2 on tissue culture plates in 10 mL apoptosis induction media (DMEM high 
glucose with no L-glutamine or sodium pyruvate (Sigma D5671), containing 1% 1M 
HEPES and 1% penicillin/streptomycin) for 16 hours at 37
o
C in 5% CO2. After 16 hours, 
floating and loosely adherent cells were collected by pipetting up and down and pelleted 
by centrifugation at 1500 rpm for 2 minutes. The percentage of these cells that were 
alive, apoptotic, and necrotic after 16 hours was determined using morphological criteria 
and trypan blue staining. Live cells were rounded with no evidence of apoptotic 
morphology and trypan blue negative, apoptotic cells were those with blebbing or 
apoptotic nuclei and trypan blue negative, and necrotic cells were those that were trypan 
blue positive. 
Phagocytosis Assay and Harvesting of Conditioned Media, RNA, and Protein 
 As described in Chapter III, non-transformed murine mammary EpH4 cells were 
plated onto 0.4 µm filters in a 24-well format until the formation of monolayers with tight 
cell-cell junctions as determined by TER, then treated with rhTGF-β3 or vehicle. Upon 
reaching a TER of at least 300 Ω*cm2, complete medium was removed from top and 
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bottom of filters, monolayers and bottom wells were washed three times with PBS, and 
45,000 apoptotic EpH4 cells were added to the top of live EpH4 monolayers in 300 µl of 
SFM, while 1 ml of SFM without apoptotic cells was added to the bottom well. For 
apoptotic cell only conditions, apoptotic cells were added to filters alone. After 18 hours 
at 37
o
C in 5% CO2, conditioned media from the top and bottom of the filter was 
combined for each well and centrifuged at 2000 rpm for 5 minutes to remove particulates. 
Supernatants were transferred to new tubes and stored at -80
o
C for future analysis. For 
wells harvested for RNA, 200 µl of TRIzol reagent was added to the monolayers 
immediately after removing conditioned media and cells were harvested using a cell lifter 
that had been modified to fit into the wells. Cells were homogenized in TRIzol by 
vigorously pipetting 20 times and stored at -80
o
C until RNA isolation. For wells 
harvested for protein, monolayers were washed twice with ice cold PBS, incubated in 100 
µl of RIPA buffer (10 µM Tris pH 7.4, 150 µM NaCl, 0.1% SDS, 1% sodium 
deoxycholate, and 1% Triton X-100) containing protease and phosphatase inhibitors (1x 
Protease Inhibitor Cocktail (Sigma), 200 µg/mL PMSF, 1 mM Na3VO4, and 50 mM NaF) 
for 5 minutes on ice, and collected using a modified cell lifter. 
Bone Marrow-Derived Macrophage (BMDM) Maturation and Activation 
 Bone marrow was harvested from tibia and femurs of 6-8 week old Balb/c mice. 
Macrophages were matured from bone marrow by plating 750,000 bone marrow cells in 
10 cm tissue culture plates in 10 mL of initial macrophage media (RPMI 1640 containing 
30% L-cell conditioned media, 10% FBS, and 1% penicillin/streptomycin) (maturation 
day 0), which was replaced on maturation day 3. On day 5, initial media was removed 
from plates and replaced with 10 mL pre-activation media (DMEM low glucose 
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containing 30% L-cell conditioned media, 10% FBS, 1% non-essential amino acids, and 
1% penicillin/streptomycin). After 24 hours of pre-activation, media was removed and 
macrophages washed in PBS, harvested in PBS using a cell lifter, and counted. Three 
hundred thousand macrophages per well were then plated in 12-well plates in 700 µl/well 
DMEM low glucose containing 30% L-cell conditioned media (BMDM media) for 24 
hours. At this point, the cell population is greater than 99% mature macrophages based on 
dual positivity for the macrophage markers F4/80 and CD11b, as determined by flow 
cytometry
40
. After 24 hours in BMDM medium, medium was removed and replaced with 
experimental conditioned media from phagocytic EpH4 cells or control activation media 
(unstimulated=BMDM medium; M1 stimulated=BMDM medium plus 5 ng/mL 
lipopolysaccharide (LPS) and 12 ng/ml IFN-γ; M2 stimulated=BMDM medium plus 10 
ng/mL IL-4) for 24 hours. After 24 hours, macrophages were washed with PBS, and 
harvested using a cell scraper. Cells from each well were split into two equal aliquots and 
pelleted by centrifugation at 1500 rpm for 2 minutes for RNA and protein, or used in 3D 
co-culture assays with murine mammary tumor D2.OR cells. For RNA, pellets were 
resuspended in 200 µl of TRIzol, homogenized by passing through a 26-gauge needle, 
and stored at -80
o
C until RNA isolation. For protein, pellets were resuspended in 50 µl of 
RIPA buffer containing protease and phosphatase inhibitors.  
Generation of L-cell Conditioned Media 
 L929 murine fibrosarcoma cells were cultured in DMDM high glucose containing 
10% FBS and 2 mM L-glutamine. For sub-culturing, cells were split 1:4-1:8 at 80% 
confluency. For generation of L-cell conditioned media, media was collected 5-7 days 





 For immunoblotting of EpH4 cells, apoptotic cells, and macrophages, 25, 30 and 
40 µg of total protein, respectively, was separated by SDS-PAGE. Membranes were 
blocked in 5% non-fat dry milk in TBS-T for 1 hour at room temperature. 
Immunoblotting was performed by incubating in primary and HRP-conjugated secondary 
antibodies, as described in Table A-1, followed by detection using ECL Western Blotting 
Substrate (Thermo Fisher Scientific, Waltham, MA). 




 Ab Company Catalog # Dilution Conditions 
AIF-1 Wako 019-19741 1:500 O/N, 4
o
C 
Arg-1 Santa Cruz Sc-18351 1:100 O/N, 4
o
C 





Cell Signaling 9664 1:500 O/N, 4
o
C 
COX-2 Cayman Chemical 160106 1:1,000 O/N, 4
o
C 
GAPDH Sigma G9545 1:5,000 1 hr, RT 
iNOS Abcam ab15323 1:100 O/N, 4
o
C 





Ab     
Anti-goat Santa Cruz sc-2922 1:10,000 1 hr, RT 
Anti-mouse Santa Cruz sc-2055 1:10,000 1 hr, RT 
Anti-rabbit Bio-Rad 170-6515 1:10,000 1 hr, RT 
 
Cytokine Array 
 Cytokine analysis was performed on undiluted and unconcentrated conditioned 
media using the Mouse Cytokine Magnetic 20-Plex Panel (Life Technologies, Carlsbad, 
CA) with a magnetic separator per manufacturer‘s protocol. Analytes analyzed were FGF 
basic, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-
17, IP-10, KC, MCP-1, MIG, MIP-1α, TNF-α, and VEGF. Data was collected using a 
Luminex MAGPIX (Luminex Corporation, Austin, TX). Three wells per condition were 
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analyzed per experiment (n=3 independent experiments) and samples were assayed in 
duplicate for a 3x3x2 assay design. Mean cytokine concentrations were determined for 
each condition per experiment, and data are reported as the mean concentration across the 
3 independent experiments. 
Prostaglandin E2 (PGE2) ELISA 
 PGE2 concentration was determined in undiluted, unconcentrated conditioned 
media using a Prostaglandin E2 Enzyme Immunoassay Kit-Monoclonal (Cayman 
Chemical, Ann Arbor, MI) per manufacturer‘s protocol. For data collection, the assay 
developed for 60 minutes and absorbance was read at 405 nm using a BioTek Synergy 2 
(BioTek, Winooski, VT). Three wells per condition were analyzed per experiment (n=3 
independent experiments) and samples were assayed singly for a 3x3x1 study design. 
Mean cytokine concentrations were determined for each condition per experiment, and 
data are reported as the mean concentration across the 3 independent experiments. 
RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR 
 For phagocytic EpH4 cells and controls, RNA isolation and cDNA synthesis were 
performed as described in Chapter III. Macrophages were harvested into TRIzol as 
described above and RNA was isolated according to the manufacturer‘s protocol (Life 
Technologies, Carlsbad, CA). For quantitative RT-PCR, 1 µl of reverse transcriptase 
reactions was combined with SYBR green (Bio-Rad Laboratories, Hercules, CA), 
forward and reverse primers at a concentration of 1 µM each, and brought up to a final 
reaction volume of 20 µl with nuclease-free water. The following primers were used, 
from Integrated DNA Technologies (Coralville, IA): actin, forward: 5‘-GCA ACG AGC  
  
130 
GGT TCC G-3‘, reverse: 5‘-CCC AAG AAG GAA GGC TGG-3‘; IL4, forward: 5‘-TCA 
CTG ACG GCA CAG AGC TAT TGA-3‘, reverse: 5‘- TTT GTC GCA TCC GTG GAT 
ATG GCT-3‘; IL10, forward: 5‘-GCT CTT GCA CTA CCA AAG CCA CAA-3‘, 
reverse: 5‘-AGT AAG AGC AGG CAG CAT AGC AGT-3‘; IL12, forward: 5‘-TGA 
TGA TGA CCC TGT GCC TTG GTA-3‘, reverse: 5‘-ATT CTG AAG TGC TGC GTT 
GAT GGC-3‘; IL13, forward: 5‘-AGC AGC TTA TTG AGG AGC TGA GCA-3‘, 
reverse: 5‘-TGG AGA TGT TGG TCA GGG AAT CCA-3‘; TGFb1, forward: 5‘-TAC 
GTC AGA CAT TCG GGA AGC AGT-3‘, reverse: 5‘-AAA GAC AGC CAC TCA 





C, 1 min 60
o
C (42 cycles); 1 min, 95
o
C, 1 min, 55
o
C. Primer specificity was 
confirmed via melt-curve analysis. Data were collected using the MyiQ Single Color 
Real-Time PCR Detection System with iQ5 software (Bio-Rad Laboratories), and gene 
expression was normalized to actin using the delta-delta Ct method. 
3D Tumor Cell-Macrophage Co-Culture, Organoid Quantification, and 
Immunohistochemistry 
 The day prior to seeding cells in 3D co-culture assays, Matrigel (BD Biosciences) 
pads were formed by plating 100 μl of stock Matrigel per well in a 96-well plate and 
allowed to solidify overnight at 37
o
C. Murine mammary D2.OR tumor cells, a kind gift 
from Ann Chambers (University of Western Ontario, London, Ontario, Canada), and 
control or conditioned media-activated bone marrow-derived macrophages were 
suspended in 200 μl/well DMEM low glucose containing 2% heat-inactivated FBS and 
seeded onto Matrigel Pads, in triplicate. Assays were placed in the incubator at 37
o
C and  
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5% CO2 for 5 days. Organoid size quantification was performed on day 5 from  
representative live cell images of the center of the wells by determining the number of 
Type 1, Type 2, Type 3, and Type 4 organoids per well. For bromodeoxyuridine (BrdU) 
incorporation, cells were treated with BrdU at a final concentration of 0.1 mM for 6 hours 





Here, we utilized an in vitro model in which EpH4 cells in a monolayer are 
induced to become phagocytic with TGF-β3 treatment and then fed apoptotic EpH4 cells. 
In this system, apoptosis is induced in EpH4 cells by withdrawing L-glutamine and serum 
from the media. To determine the length of time required for L-glutamine and serum 
withdrawal to induce apoptosis in EpH4 cells, a western blot was performed for the 
cleaved version of caspase 3, an executioner caspase in both the intrinsic and extrinsic 
apoptosis pathways that requires cleavage for activation. Cleaved caspase-3 was 
detectable at 12 hours post-apoptosis induction and peaked at 20 hours post-induction 
(Figure A-1A). Because the activation of caspase-3 in apoptotic cells is preceded by other 
steps of the apoptosis program, including phosphatidylserine exposure on the outer leaflet 
of the cell membrane, cells were harvested at 16 hours post-apoptosis induction for use in 
subsequent assays, prior to the peak in cleaved caspase-3. At 16 hours post-induction, 
67% percent of the cells were apoptotic by morphological criteria and trypan blue 
exclusion, while 23% were determined to be live and 10% had progressed to secondary 
necrosis (Figure A-1B). 
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Figure A-1. Characterization of EpH4 cells after culture in apoptosis-inducing 
conditions. A) Western blot (top) and quantification (bottom) of cleaved-caspase 3 and 
GAPDH after 0-24 hours in apoptosis-inducing media. B) Representative image (top) and 
quantification (bottom) of percent live (pink arrowheads), apoptotic (yellow arrows), and 
necrotic (black asterisks) EpH4 cells after 16 hours. 
  
VEGF, Cytokine, and PGE2 Secretion by Efferocytic Mammary Epithelial Cells 
Following engulfment of apoptotic cells, macrophages secrete 
immunosuppressive factors such as IL-10, TGF-β, and PGE2
92
. To determine if 
efferocytic mammary epithelial cells similarly promote an immunosuppressive 
environment through the production of soluble factors, mature EpH4 mammary epithelial 
cell monolayers were treated with TGF-β3 to induce a phagocytic phenotype, followed 
by incubation with apoptotic EpH4 cells in serum free media (SFM). As controls, 
monolayers were also vehicle (Veh) treated followed by SFM instead of apoptotic cells 
(Veh/SFM), vehicle treated and incubated with apoptotic cells (Veh/A.C.), or treated with 
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TGF-β3 followed by SFM (Figure A-2). To determine cytokine secretion by phagocytic 
mammary epithelial cells, conditioned media from efferocytic mammary epithelial cells 
and controls was analyzed using a Mouse Cytokine Magnetic 20-Plex Panel. All analytes 
analyzed were below the limit of detection of the assay, with the exception of VEGF, 
interferon γ-induced protein 10 (IP-10, also known as CXCL10), and keratinocyte-
derived chemokine (KC, also known as GRO1/CXCL1), which was detected in only one 
of three experiments and at similar levels (~40-50 pg/ml) across conditions (data not 
shown). VEGF was detected in the media from all conditions, and was highest in 
conditioned media from fully efferocytic mammary epithelial cells which had been 
treated with TGF-β3 to induce a phagocytic phenotype then incubated with apoptotic 
cells (TGF-β3/A.C.). VEGF levels in conditioned media from fully efferocytic mammary 
epithelial cells was, on average, 1.6-fold higher than control EpH4 cell monolayers 
(Veh/SFM), and this increase in VEGF was not simply an additive effect of increased 
VEGF due to apoptotic cells and TGF-β3 treatment alone (Veh/A.C. and TGF-β3/SFM, 
respectively) (Figure A-3A). These data are consistent with the work of others 
demonstrating VEGF secretion by non-transformed murine mammary HC11 cells 
following incubation with apoptotic Jurkat T cells
259
. In addition to VEGF, in two out of 
three experiments, IP-10 was detected in conditioned media from EpH4 cells that had 
been treated with TGF-β3 regardless of whether or not the cells were subsequently 
incubated with apoptotic cells (Figure A-3B). While additional experiments need to be 




Figure A-2. Schematic of experimental conditions for in vitro efferocytosis assay. 
Mature EpH4 cell monolayers grown on transwell filters were treated with vehicle or 
TGF-β3 for 24 hours, followed by incubation with apoptotic cells (A.C.) or serum-free 
media (SFM) for an additional 18 hours. 
 
 
Though cytokines traditionally involved in the alternative activation of 
macrophages (IL-4, IL-10, and IL-13) were included in the conditioned media analysis, 
using the Mouse Cytokine Magnetic 20-Plex Panel, none were present at levels above the 
limit of detection of the assay (data not shown). Therefore, as an alternative approach, q-
RT-PCR was used to determine if IL4, IL10, or IL13, as well as TGFb1 gene expression 
was upregulated in efferocytic mammary epithelial cells. No significant changes were 
observed in any of the four cytokines analyzed for any condition (Figure A-3C-F). 
Altogether, these data do not support a role for secretion of IL4, IL10, IL13, and TGFb1 
by efferocytic mammary epithelial cells in this model.  
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Figure A-3. Cytokine production by mammary epithelial cells that have engulfed 
apoptotic cells in vitro. A and B) Conditioned media analysis demonstrates VEGF 
secretion by fully efferocytic EpH4 cells (A) and IP-10 secretion following TGF-β3 
treatment. C-F) q-RT-PCR for TGFb1, IL10, IL4, and IL13 expression by efferocytic 
EpH4 cells and controls demonstrates no significant differences between groups. 
 
In addition to cytokines, prostaglandins (PG) are also known to play a role in 
immune modulation following engulfment of apoptotic cells, particularly PGE2
92
. PGE2 
is formed via COX conversion of arachidonic acid to PGH2 followed by conversion to 
PGE2 by prostaglandin synthase
273
. There are two COX enzymes involved in PG 
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synthesis, COX-1 and COX-2. Because COX-1 is primarily involved in the establishment 
and maintenance of baseline PG levels and COX-2 is the induced form of the enzyme 
with roles in the induction of prostaglandin synthesis for immune modulation, we 
investigated COX-2 expression in efferocytic mammary epithelial cells. By immunoblot, 
TGF-β3 treatment alone (TGF-β3/SFM) resulted in the greatest increase in COX-2 
expression by EpH4 cells (Figure A-4A). Compared to TGF-β3 treatment alone, fully 
efferocytic cells that had been treated with TGF-β3 and fed apoptotic cells (TGF-
β3/A.C.) had significantly lower levels of COX-2 expression, which was higher than 
EpH4 cell monolayers alone (Veh/SFM) (Figure A-4A). These data indicate that contrary 
to our prediction of increased COX-2 expression upon engulfment of apoptotic cells, the 
addition of apoptotic cells to TGF-β3-treated EpH4 cells led to decreased COX-2 
expression in this model. COX-2 expression has not previously been evaluated in 
efferocytic cells that have been treated with TGF-β so it is possible that in this context 
apoptotic cells do not induce further increases in COX-2 expression. In support of this 
possibility, apoptotic cell added to untreated EpH4 cells did result in increased COX-2 
expression, though not statistically significant, indicating that the apoptotic cells used in 
these assays have the ability to induce COX-2 expression, but not in the context of pre-
treatment with TGF-β3. Additionally, the apoptotic cells used in the assay may also have 
influenced COX-2 levels in the phagocytes. Morphological characterization of apoptotic 
cells used in this assay indicates that ~10% of the cells had progressed to secondary 
necrosis at the time the cells were harvested for use in the assay. In contrast to apoptosis, 




experiments could be done to test if the difference in response to necrotic cells versus 
apoptotic cells could contribute to decreased COX-2 expression in these cells.  
To determine if COX-2 expression correlated with production of PGE2, PGE2 
levels were measured in conditioned media from efferocytic mammary epithelial cells 
and controls. PGE2 was detected in all conditioned media, with a trend toward increased 
levels in EpH4 cell monolayers that had been incubated with apoptotic cells, independent 
of whether or not the cells were pretreated with vehicle (Veh/A.C.) or TGF-β3 (TGF-
β3/A.C.) (Figure A-4B). However, based on detectable levels of PGE2 in conditioned 
media from apoptotic cells only, it is difficult to discern whether increased PGE2 in 
conditioned media from Veh/A.C. and TGF-β3/A.C. conditions is a result of 
phagocytosis or an additive effect of apoptotic cells alone and untreated monolayers. 
Macrophage Activation by Efferocytic Mammary Epithelial Cells 
To determine if efferocytic mammary epithelial cells promote the alternative 
activation of macrophages, bone marrow-derived macrophages were treated with 
conditioned media from TGF-β3-treated EpH4 cell monolayers that had been incubated 
with apoptotic cells and controls. As positive controls, macrophages were treated with 
LPS plus IFN-γ to induce classical activation and IL-4 to induce alternative activation. As 
expected based on the current understanding of classically and alternatively activated 
macrophages, classically activated macrophages upregulated iNOS, while alternatively 
activated macrophages upregulated MR and Arg-1 (Figure A-5A). Additionally, 
classically activated macrophages also upregulated expression of allograft inflammatory 
factor 1 (AIF-1) and COX-2, while alternatively activated macrophages had decreased 
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Figure A-4. COX-2 expression and PGE2 production by efferocytic mammary 
epithelial cells. A) Immunoblot (top) and quantification (bottom) of COX-2 expression 
in efferocytic EpH4 cells and controls. B) PGE2 ELISA using conditioned media from 
efferocytic EpH4 cells and controls, reported as absolute levels (left) and fold-changed 
compared to Veh/SFM (right). 
 
expression of AIF-1 compared to macrophages that had not been activated (Figure A-
5A). Lastly, CD86, a T cell co-stimulatory molecule expressed on mature macrophages, 
did not vary significantly between unstimulated and classically or alternatively activated 
macrophages (Figure A-5A). When macrophages were treated with conditioned media 
from TGF-β3-treated EpH4 cells, downregulation of MR and AIF-1 was observed, 
regardless of whether or not EpH4 cells were exposed to apoptotic cells (Figure A-5B). 
This is consistent with characteristics of both classically and alternatively activated 
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macrophages, respectively. Reduced CD86 expression, suggestive of reduced ability to 
activate T cells, was also observed in macrophages treated with conditioned media from 
fully phagocytic EpH4 cells (TGF-β3/A.C.), while a slight, but repeatable increase in 
Arg-1 was observed in macrophages treated with conditioned media from EpH4 cells that 
had been exposed to apoptotic cells (Figure A-5B), consistent with alternative 
macrophage activation. iNOS and COX-2 expression were also evaluated in macrophages 
following conditioned media treatment; however, results were inconsistent across 
experiments so no conclusions could be drawn.  
 To begin to address the question of whether macrophages treated with 
conditioned media have any tumor-promotional properties, conditioned-media exposed 
macrophages and murine mammary D2.OR tumor cells were co-cultured on Matrigel 
pads. The resultant organoid structures were quantified based on size and morphological 
criteria, with Type 1 organoids being small, rounded structures, Type 2 organoids having 
slightly larger size with minimal invasive structures, Type 3 organoids being larger, with 
some invasive projections, and Type 4 organoids being very invasive-looking (Figure A-
6A). Organoid structures resulting from co-culture with macrophages treated with 
conditioned media from control EpH4 monolayers (Veh/SFM), EpH4 cells incubated 
with apoptotic cells (Veh/A.C.), and fully efferocytic EpH4 cells (TGF-β3/A.C.) were 
predominantly Type 1 and Type 2 (Figure A-6B). However, macrophages treated with 
conditioned media from EpH4 cells treated with TGF-β3 (TGF-β3/Veh) resulted in a 
shift in organoids from predominantly Type 1 and Type 2 structures, to Type 2 and Type 
3 structures, with some evidence of very invasive Type 4 organoids (Figure A-6B). BrdU   
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Figure A-5. Conditioned media from efferocytic mammary epithelial cells promotes 
macrophages with both classically and alternatively activated characteristics. A) 
Immunoblot of control macrophages following classical activation with LPS and IFNγ 
and alternative activation with IL-4. B) Immunoblot (left) and quantification (right) of 
macrophages activated with conditioned media from efferocytic mammary epithelial cells 
and controls. 
 
incorporation did not significantly vary between groups (Figure A-6C), indicating 
differences in organoid type are likely not driven by changes in proliferation.  
Discussion 
Postpartum mammary gland involution is a period of tissue remodeling following 
lactation, or pregnancy in the absence of nursing, with known roles in tumor promotion
47, 
57, 61, 62
. During involution, the mammary epithelial cells are the primary cell type 
responsible for apoptotic cell clearance
76, 98
. In general, the immune milieu in areas of 
apoptotic cell clearance shares many similarities with tumor-promotional immune 
environments; therefore, we utilized an in vitro model to investigate the immune 
modulatory properties of efferocytic mammary epithelial cells
128
. In this model, 
141 
 
Figure A-6. Macrophages activated with conditioned media from TGF-β3-treated 
EpH4 cells promote more invasive organoid structures. A) Representative images of 
Type 1, 2, 3, and 4 organoids used for quantification of macrophage-D2.OR co-cultures. 
B) Quantification of resultant organoid structures when macrophages activated by 
efferocytic EpH4 cell conditioned media were co-cultured with D2.OR tumor cells. C) 
BrdU incorporation into macrophage-D2.OR organoids does not vary by condition. 
 
efferocytic mammary epithelial cells have increased VEGF production and promote a 
macrophage phenotype that has characteristics of both classical and alternative activation. 
 Our data demonstrating increased production of VEGF in response to apoptotic 
cells is consistent with work from others also demonstrating increased VEGF secretion 




. If mammary epithelial cells in vivo also produce increased VEGF upon 
engulfment of apoptotic cells, this may have important consequences for postpartum 
breast cancer. The development of solid tumors dependent on angiogenesis and VEGF 
has been identified as a main factor promoting angiogenesis in tumors, through the 
promotion of proliferation and migration of endothelial cells
235, 238, 274-277
. Additionally, 
VEGF can also directly promote growth of tumor cells, independent of its effect on 
angiogenesis
234, 236, 237
. In breast cancer, VEGF expression is significantly correlated with 
microvessel density, and increased VEGF levels are a poor prognostic indicator
278-281
. In 
premenopausal breast cancer specifically, VEGF expression is a predictor of recurrence 
within 2.25 years of diagnosis
282
. Mouse models and in vitro studies have demonstrated a 
direct role for VEGF in mammary tumor growth, invasion and metastasis, and 
microvessel density
283-285
. Presently, a role for VEGF has not been identified in 
postpartum involution or postpartum breast cancer. Future work should be directed 
toward determining if mammary epithelial cells secrete VEGF in vivo in response to 
apoptotic cells engulfment, through immunohistochemical techniques and in situ 
hybridization. Additional in vitro studies may be performed to determine the effect of 
VEGF secretion by efferocytic mammary epithelial cells on endothelial cell proliferation 
and migration, as well as direct effects on tumor cell proliferation, motility, and invasion. 
 In the work described here, conditioned media from phagocytic mammary 
epithelial cells promoted a macrophage phenotype that shared characteristics of both 
classically activated and alternatively activated macrophages. Similar to involution 
macrophages, which have been characterized as alternatively activated based on Arg-1 
expression, Arg-1 was increased in macrophages that had been treated with conditioned 
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media from EpH4 cells that had been exposed to apoptotic cells
55
. Also consistent with 
promotion of alternatively activated macrophages by efferocytic mammary epithelial 
cells, macrophages treated with conditioned media from EpH4 cells primed for 
phagocytosis with TGF-β3 treatment downregulated AIF-1, similar to IL-4 stimulated 
alternatively activated control macrophages. However, unlike alternatively activated 
macrophages, these same macrophage treatment conditions were also associated with 
decreased mannose receptor expression, which is more characteristic of a classically 
activated phenotype.  
Unlike any of the of control macrophage populations, including alternatively 
activated macrophages, downregulation of CD86 was observed only in macrophages 
treated with conditioned media from fully efferocytic EpH4 cells. This has important 
implications in the microenvironments of apoptotic cell clearance and cancer. CD86 is a 
cell-surface protein expressed by antigen presenting cells that functions as a co-
stimulatory molecule, along with CD80, in the activation of T cells. CD80 and CD86 
have been shown to regulate self-tolerance, with lack of co-stimulation from CD80 and 
CD86 generally being associated with increased tolerance
286
. However, there are also 
data to suggest that CD80 and CD86 may differentially regulate tolerance, with CD80 
expression leading to increased immune suppression and CD86 contributing to reduced 
immune suppression
287
. Promotion of CD86 downregulation on macrophages by 
efferocytic mammary epithelial cells indicates these macrophages may be deficient in 
their ability to activate T cells, and is consistent with an immune tolerant state. In the 
context of the massive amount of apoptosis during involution, this would benefit the host 
by preventing activation of the immune system against self-antigens should the apoptotic 
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cells not be cleared rapidly. However, if CD86 is downregulated on macrophages during 
involution in the context of cancer cells, this is predicted to contribute to immune evasion 
by the cancer. A limitation of the current work is in the inability to determine whether 
decreased CD86 expression by efferocytic mammary epithelial cell-activated 
macrophages associates with a deficiency in these macrophages to activate T cells. 
Additional studies should be performed to assess T cell activation by these macrophages, 
as well as to evaluate CD80 expression. 
 In 3D cell culture, macrophages treated with conditioned media from TGF-β3-
treated EpH4 cells promoted the largest and most invasive organoid structures when co-
cultured with D2.OR mouse mammary tumor cells. One interpretation of these data is 
that residual TGF-β3 could be in the media from treatment of EpH4 cell monolayers; 
however, this is unlikely due washing of the monolayer 3 times after removing medium 
containing TGF-β3, prior to the addition of apoptotic cells. To directly test for residual 
TGF-β3 in the medium, an ELISA for rhTGF-β3 may be performed. Further 
understanding the tumor-promotional properties of macrophage activated by TGF-β3-
treated mammary epithelial cells is of interest, given the dramatic upregulation of TGF-β 
in the involuting mammary gland
37, 57, 161, 162
. BrdU data do not support a role for 
proliferation in driving the differences in organoid phenotype; therefore, alternatives such 
as changes in apoptosis and tumor cell adhesion, motility, and invasiveness should be 
explored. Macrophages activated by fully efferocytic mammary epithelial cell 
conditioned media did not further increase organoid size or number of invasive cells over 
the TGF-β3-only condition, and in fact had little effect on organoid size and invasiveness 
in 3D cell culture. This result is somewhat unexpected given that macrophages engulfing 
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apoptotic cells have been shown to produce growth and survival factors
128
. However, the 
fact that macrophages activated with conditioned media from efferocytic mammary 
epithelial cells did not induce larger, more invasive organoids in this assay does not rule 
out a role for efferocytic mammary epithelial cells contributing to a tumor-promotional 
environment. Efferocytic mammary epithelial cells may be directly tumor-promotional 
themselves, independent of an interaction with macrophages. To test the direct effects of 
efferocytic mammary epithelial cells on tumor promotion, conditioned media from 
efferocytic mammary epithelial cells and controls may be used to treat tumor cells 
directly, and assess for changes in tumor cell proliferation, invasion, and motility. 
Additionally, the 3D co-culture assay described here does not address the role of 
apoptotic cell clearance by mammary epithelial cells in the promotion of immune 
suppression in the local environment. Both efferocytic mammary epithelial cells and the 
macrophages they activate may function in promoting local immune suppression. To 
address this question, additional assays may be performed which assess T cell 
suppression and activation by efferocytic mammary epithelial cells and the macrophages 
they activate. 
 The involution-hypothesis predicts that the wound healing attributes of 
postpartum involution contribute to the promotion of cancer cells that are present in the 
gland at this time
28
. Efferocytic mammary epithelial cells may contribute to the wound 
healing attributes of postpartum involution by producing VEGF and influencing the 
involuting macrophage phenotype. Additional studies to further characterize these events 
will expand upon our current knowledge of the dynamic interactions between phagocytic 
mammary epithelial cells and the local immune milieu of the involuting gland. 
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Interventions that sway the efferocytic mammary epithelial cells away from tumor 
promotion may provide novel approaches to reduce postpartum breast cancer incidence 
and progression. 
